Clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with uncomplicated symptomatic gallstones or cholecystitis: a systematic review and economic evaluation

Miriam Brazzelli, Moira Cruickshank, Mary Kilonzo, Irfan Ahmed, Fiona Stewart, Paul McNamee, Andrew Elders, Cynthia Fraser, Alison Avenell and Craig Ramsay
Clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with uncomplicated symptomatic gallstones or cholecystitis: a systematic review and economic evaluation

Miriam Brazzelli,1* Moira Cruickshank,1 Mary Kilonzo,2 Irfan Ahmed,3 Fiona Stewart,1 Paul McNamee,2 Andrew Elders,1 Cynthia Fraser,1 Alison Avenell1 and Craig Ramsay1

1Health Services Research Unit, University of Aberdeen, Aberdeen, UK
2Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
3NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK

*Corresponding author

Declared competing interests of authors: none

Published August 2014
DOI: 10.3310/hta18550

This report should be referenced as follows:

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/Clinical Medicine.*
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 12/16/01. The contractual start date was in August 2012. The draft report began editorial review in May 2013 and was accepted for publication in October 2013. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2014. This work was produced by Brazzelli et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor Jane Norman  Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, University College London, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk
Abstract

Clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with uncomplicated symptomatic gallstones or cholecystitis: a systematic review and economic evaluation

Miriam Brazzelli,1* Moira Cruickshank,1 Mary Kilonzo,2 Irfan Ahmed,3 Fiona Stewart,1 Paul McNamee,2 Andrew Elders,1 Cynthia Fraser,1 Alison Avenell1 and Craig Ramsay1

1Health Services Research Unit, University of Aberdeen, Aberdeen, UK
2Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
3NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK

*Corresponding author

Background: Approximately 10–15% of the adult population suffer from gallstone disease, cholelithiasis, with more women than men being affected. Cholecystectomy is the treatment of choice for people who present with biliary pain or acute cholecystitis and evidence of gallstones. However, some people do not experience a recurrence after an initial episode of biliary pain or cholecystitis. As most of the current research focuses on the surgical management of the disease, less attention has been dedicated to the consequences of conservative management.

Objectives: To determine the clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management in people presenting with uncomplicated symptomatic gallstones (biliary pain) or cholecystitis.

Data sources: We searched all major electronic databases (e.g. MEDLINE, EMBASE, Science Citation Index, Bioscience Information Service, Cochrane Central Register of Controlled Trials) from 1980 to September 2012 and we contacted experts in the field.

Review methods: Evidence was considered from randomised controlled trials (RCTs) and non-randomised comparative studies that enrolled people with symptomatic gallstone disease (pain attacks only and/or acute cholecystitis). Two reviewers independently extracted data and assessed the risk of bias of included studies. Standard meta-analysis techniques were used to combine results from included studies. A de novo Markov model was developed to assess the cost-effectiveness of the interventions.

Results: Two Norwegian RCTs involving 201 participants were included. Eighty-eight per cent of people randomised to surgery and 45% of people randomised to observation underwent cholecystectomy during the 14-year follow-up period. Participants randomised to observation were significantly more likely to experience gallstone-related complications [risk ratio = 6.69; 95% confidence interval (CI) 1.57 to 28.51; p = 0.01], in particular acute cholecystitis (risk ratio = 9.55; 95% CI 1.25 to 73.27; p = 0.03), and less likely to undergo surgery (risk ratio = 0.50; 95% CI 0.34 to 0.73; p = 0.0004), experience surgery-related complications (risk ratio = 0.36; 95% CI 0.16 to 0.81; p = 0.01) or, more specifically, minor surgery-related complications.
complications (risk ratio = 0.11; 95% CI 0.02 to 0.56; p = 0.008) than those randomised to surgery. Fifty-five per cent of people randomised to observation did not require an operation during the 14-year follow-up period and 12% of people randomised to cholecystectomy did not undergo the scheduled operation. The results of the economic evaluation suggest that, on average, the surgery strategy costs £1236 more per patient than the conservative management strategy but was, on average, more effective. An increase in the number of people requiring surgery while treated conservatively corresponded to a reduction in the cost-effectiveness of the conservative strategy. There was uncertainty around some of the parameters used in the economic model.

**Conclusions:** The results of this assessment indicate that cholecystectomy is still the treatment of choice for many symptomatic people. However, approximately half of the people in the observation group did not require surgery or suffer complications in the long term indicating that a conservative therapeutic approach may represent a valid alternative to surgery in this group of people. Owing to the dearth of current evidence in the UK setting a large, well-designed, multicentre trial is needed.

**Study registration:** The study was registered as PROSPERO CRD42012002817

**Funding:** The National Institute for Health Research Health Technology Assessment programme.
## Contents

**List of tables**

*ix

**List of figures**

*xi

**List of abbreviations**

*xiii

**Plain English summary**

*xv

**Scientific summary**

*xvii

**Chapter 1** Background

1

Description of health problem

1

Current service provision

4

Description of technologies under assessment

5

**Chapter 2** Definition of the decision problem

7

Decision problem

7

Overall aims and objectives of assessment

8

**Chapter 3** Methods of the systematic review of clinical effectiveness

9

Identification of studies

9

Inclusion and exclusion criteria

9

Data extraction strategy

11

Critical appraisal strategy

11

Methods of data synthesis

11

**Chapter 4** Clinical effectiveness of cholecystectomy compared with observation/conservative management

13

Quantity of research available

13

Assessment of clinical effectiveness

19

Overview of outcomes included in meta-analyses

19

Relevant outcomes according to the treatment received by participants

30

Outcomes not included in meta-analyses

32

Summary

33

**Chapter 5** Assessment of cost-effectiveness

37

Systematic review of existing cost-effectiveness evidence

37

Economic modelling

37

Results

47

**Chapter 6** Discussion

55

Summary of findings

55

Strengths and limitations of the assessment

60

**Chapter 7** Conclusions

63

Implications for health care

63

Suggested research priorities

63
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acknowledgements</td>
<td>65</td>
</tr>
<tr>
<td>References</td>
<td>67</td>
</tr>
<tr>
<td><strong>Appendix 1</strong> Search strategies</td>
<td>77</td>
</tr>
<tr>
<td><strong>Appendix 2</strong> Full-text screening form</td>
<td>85</td>
</tr>
<tr>
<td><strong>Appendix 3</strong> Data extraction form</td>
<td>87</td>
</tr>
<tr>
<td><strong>Appendix 4</strong> Risk of bias form</td>
<td>93</td>
</tr>
<tr>
<td><strong>Appendix 5</strong> List of included and excluded studies</td>
<td>97</td>
</tr>
</tbody>
</table>
List of tables

TABLE 1 Demographic information of included studies 15
TABLE 2 Key features of included studies 16
TABLE 3 Risk of bias table (Schmidt et al. 2011) 18
TABLE 4 Risk of bias table (Schmidt et al. 2011) 18
TABLE 5 Findings of included studies 20
TABLE 6 Summary of meta-analysis results (n = 201 in two trials) 34
TABLE 7 Summary of probability parameters used in model 42
TABLE 8 All-cause age-specific mortality rates 42
TABLE 9 Summary of unit costs used in the analysis 43
TABLE 10 Quality-of-life estimates 45
TABLE 11 Base-case analysis 48
TABLE 12 Cost-effectiveness of conservative management vs. surgery: effect of varying the probability of people needing surgery after conservative management 49
TABLE 13 Cost-effectiveness of conservative management vs. surgery: effect of varying the probability of surgical complications 50
TABLE 14 Cost-effectiveness of conservative management vs. surgery assuming individuals have an inpatient stay 50
TABLE 15 Cost-effectiveness of conservative management vs. surgery assuming different utility values for individuals who remain symptomatic in conservative management 51
TABLE 16 Cost-effectiveness of conservative management vs. surgery: effect of varying annual discount rates 53
TABLE 17 Cost-effectiveness of conservative management vs. surgery: effect of increasing the follow-up to 10 years 54
<table>
<thead>
<tr>
<th>FIGURE</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Biliary system</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Flow chart of the clinical decision-making process for people with symptomatic uncomplicated gallstone disease</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>Flow chart for the identification and selection of studies</td>
<td>14</td>
</tr>
<tr>
<td>4</td>
<td>Risk of bias graph for both included studies</td>
<td>18</td>
</tr>
<tr>
<td>5</td>
<td>Risk of bias summary figure</td>
<td>19</td>
</tr>
<tr>
<td>6</td>
<td>Forest plot of participants having surgery (14 years)</td>
<td>22</td>
</tr>
<tr>
<td>7</td>
<td>Forest plot of pain attacks (14 years)</td>
<td>22</td>
</tr>
<tr>
<td>8</td>
<td>Forest plot of total gallstone-related complications (14 years)</td>
<td>24</td>
</tr>
<tr>
<td>9</td>
<td>Forest plot of episodes of acute cholecystitis (14 years)</td>
<td>24</td>
</tr>
<tr>
<td>10</td>
<td>Forest plot of episodes of CBD stones (14 years)</td>
<td>24</td>
</tr>
<tr>
<td>11</td>
<td>Forest plot of episodes of acute pancreatitis (14 years)</td>
<td>25</td>
</tr>
<tr>
<td>12</td>
<td>Forest plot of total surgery-related complications (5 years)</td>
<td>25</td>
</tr>
<tr>
<td>13</td>
<td>Forest plot of intra-abdominal complications – infection/bile leakage (5 years)</td>
<td>26</td>
</tr>
<tr>
<td>14</td>
<td>Forest plot of episodes of wound infection/dehiscence (5 years)</td>
<td>26</td>
</tr>
<tr>
<td>15</td>
<td>Forest plot bile duct injury cases (5 years)</td>
<td>28</td>
</tr>
<tr>
<td>16</td>
<td>Forest plot of reoperation cases (5 years)</td>
<td>28</td>
</tr>
<tr>
<td>17</td>
<td>Forest plot of minor complications (5 years)</td>
<td>28</td>
</tr>
<tr>
<td>18</td>
<td>Forest plot of number of admissions due to gallstone-related pain (5 years)</td>
<td>29</td>
</tr>
<tr>
<td>19</td>
<td>Forest plot of number of deaths (14 years)</td>
<td>29</td>
</tr>
<tr>
<td>20</td>
<td>Outcomes according to treatment received (both trials combined)</td>
<td>30</td>
</tr>
<tr>
<td>21</td>
<td>Outcomes for the treatment received by participants with uncomplicated symptomatic gallstone disease only (Schmidt et al. 2011)</td>
<td>31</td>
</tr>
<tr>
<td>22</td>
<td>Outcomes according to the treatment received by participants with acute cholecystitis only (Schmidt et al. 2011)</td>
<td>31</td>
</tr>
<tr>
<td>23</td>
<td>Summary of meta-analyses results (5-year data) [risk ratio (95% CI)]</td>
<td>35</td>
</tr>
</tbody>
</table>
LIST OF FIGURES

FIGURE 24 Summary of meta-analyses results (14-year data) [risk ratio (95% CI)] 35
FIGURE 25 Surgery care pathway 38
FIGURE 26 Conservative management care pathway 38
FIGURE 27 Markov model structure 39
FIGURE 28 Cost-effectiveness acceptability curve determined by society’s willingness to pay for an additional QALY 48
# List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBD</td>
<td>common bile duct</td>
</tr>
<tr>
<td>CEAC</td>
<td>cost-effectiveness acceptability curve</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>European Quality of Life-5 Dimensions</td>
</tr>
<tr>
<td>ESWL</td>
<td>extracorporeal shock wave lithotripsy</td>
</tr>
<tr>
<td>EVPI</td>
<td>expected value of perfect information</td>
</tr>
<tr>
<td>GP</td>
<td>general practitioner</td>
</tr>
<tr>
<td>HRG</td>
<td>health-care resource group</td>
</tr>
<tr>
<td>ICER</td>
<td>incremental cost-effectiveness ratio</td>
</tr>
<tr>
<td>MeSH</td>
<td>medical subject heading</td>
</tr>
<tr>
<td>MTBE</td>
<td>methyl tert-butyl ether</td>
</tr>
<tr>
<td>NHP</td>
<td>Nottingham Health Profile part II</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>NMB</td>
<td>net monetary benefit</td>
</tr>
<tr>
<td>PGWB</td>
<td>Psychological General Well Being index</td>
</tr>
<tr>
<td>QALY</td>
<td>quality-adjusted life-year</td>
</tr>
<tr>
<td>QoL</td>
<td>quality of life</td>
</tr>
<tr>
<td>RCT</td>
<td>randomised controlled trial</td>
</tr>
<tr>
<td>SAGES</td>
<td>Society of American Gastrointestinal and Endoscopic Surgeons</td>
</tr>
<tr>
<td>VAPS</td>
<td>Visual Analogue Pain Score</td>
</tr>
</tbody>
</table>
Plain English summary

Gallstones are common, especially in women, but in many people they do not cause any symptoms.

About one in three people with gallstones develop symptoms. Symptoms usually include a severe pain in the upper right-hand side of the abdomen (known as ‘biliary colic’), and sometimes nausea and vomiting. Sometimes the pain is accompanied by inflammation of the gallbladder (cholecystitis).

Once gallstones start giving symptoms, painkillers, anti-inflammatory medicines and antibiotics are usually prescribed.

Surgery to remove the gallbladder, known as cholecystectomy, is the most common way to treat biliary pain or cholecystitis due to gallstones. About 70,000 cholecystectomies are performed every year in the UK, with significant costs for the NHS.

In the UK, surgery is commonly offered to people who present at secondary care with pain or cholecystitis due to gallstones. However, it is known that some patients do not have any more symptoms after the initial episode of pain and that surgery may not be necessary. This assessment has shown that some people with mild symptoms do not experience a recurrence or suffer complications for many years. A policy of ‘conservative treatment’ (painkillers/antibiotics and lifestyle advice) could, therefore, be appropriate in this group of people. Our results indicate that, for the NHS, surgery is more expensive than ‘conservative treatment’ but is still the most clinically effective treatment for gallstones. There are, however, great uncertainties in the data. There is a need for new clinical studies to address these uncertainties.
Scientific summary

Background

Gallstone disease, cholelithiasis, is the most common and costly gastrointestinal disorder in industrialised countries. Prevalence increases with age and obesity and is higher in women than in men.

In about 20% of people, the condition is symptomatic and can cause severe pain and complications which require medical attention and/or emergency surgery. Cholecystectomy, the surgical removal of the gallbladder, is the treatment of choice for people who present with biliary pain or acute cholecystitis and evidence of gallstones. Nowadays cholecystectomy is performed preferably by means of laparoscopic procedures. However, some people, after an initial episode of biliary pain or cholecystitis, do not experience persistent symptoms or complications. Natural history and population-based studies have shown that around half of symptomatic people do not experience further episodes of pain. There is, therefore, an indication that uncomplicated symptomatic gallstone disease (biliary pain or cholecystitis) does not always require removal of the gallbladder and could be treated conservatively. This assessment was designed to help inform decisions regarding the use in clinical practice of conservative management and cholecystectomy for adults with uncomplicated symptoms or cholecystitis. In particular, this assessment aimed to:

- describe the clinical care pathways of uncomplicated symptomatic gallstone disease (biliary pain or cholecystitis) in a UK NHS context
- determine the clinical effectiveness and safety of conservative management compared with cholecystectomy
- perform a systematic review of the evidence available on the cost-effectiveness of cholecystectomy compared with conservative management
- determine which treatment option is most likely to be cost-effective for implementation in the UK NHS
- identify and prioritise future research needs.

Methods

We searched major bibliographic electronic databases from 1980 to September 2012 including MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, the Science Citation Index, Bioscience Information Service and the Cochrane Central Register of Controlled Trials. Reports of relevant evidence syntheses were also sought from the Cochrane Database of Systematic Reviews and the Database of Abstracts of Review of Effects. Evidence was considered from randomised controlled trials (RCTs) or non-randomised comparative studies in which people received either cholecystectomy or observation/conservative management. The population was adults with first episode of symptomatic gallstone disease (biliary pain or cholecystitis) being considered for surgical treatment in a secondary care setting. The intervention considered was cholecystectomy (open or laparoscopic). The comparator was observation and/or conservative management. One reviewer screened the titles and abstracts of all reports identified by the search strategies and two reviewers independently screened all full-text papers retrieved for this assessment. Two reviewers independently extracted data and assessed the risk of bias of included studies. Standard meta-analysis techniques were used to combine results from included studies.

A de novo Markov model was developed to assess the cost-effectiveness of observation/conservative management compared with cholecystectomy. Parameter estimates were derived from the systematic review of clinical effectiveness, current literature, the expert advisory group for this assessment and other UK sources. The outputs of the model were costs and quality-adjusted life-years (QALYs) for each
treatment strategy, incremental costs and QALYs and incremental cost per QALY for a 5-year time horizon. Costs were considered from a health services perspective. Costs were discounted at 3.5% per year in accordance with the current National Institute for Health and Care Excellence guidelines. Probabilistic and deterministic sensitivity analyses were applied to the model in order to assess the robustness of the results to realistic variations in the model parameters.

Results

Clinical effectiveness
The literature searches identified 6779 potentially relevant citations, of which 73 reports were selected for full-text eligibility screening. Two RCTs published in six reports and involving 201 participants were subsequently deemed suitable for inclusion. Both trials, conducted in Norway, were considered to be at low risk of bias for all assessed quality domains. The results demonstrated that 88% of people randomised to surgery and 45% of people randomised to observation eventually underwent cholecystectomy during the 14-year follow-up period. Participants randomised to observation were significantly more likely to experience gallstone-related complications [risk ratio = 6.69; 95% confidence interval (CI) 1.57 to 28.51; p = 0.01], in particular acute cholecystitis (risk ratio = 9.55; 95% CI 1.25 to 73.27; p = 0.03), and less likely to undergo surgery (risk ratio = 0.50; 95% CI 0.34 to 0.73; p = 0.0004), experience surgery-related complications (risk ratio = 0.36; 95% CI 0.16 to 0.81; p = 0.01) or, more specifically, minor surgery-related complications (risk ratio = 0.11; 95% CI 0.02 to 0.56; p = 0.008) than those participants randomised to surgery. Among participants with an initial diagnosis of uncomplicated symptomatic gallstones (biliary pain only) rather than cholecystitis, those randomised to observation were significantly more likely to experience pain attacks after randomisation ($\chi^2 = 9.10; p = 0.0026$) and to be admitted to hospital for gallstone-related pain ($\chi^2 = 7.79; p = 0.0053$) than those randomised to surgery. Mortality risk was greater (but not significantly greater) among participants randomised to surgery. Fifty-five per cent of people randomised to observation did not require an operation during the 14-year follow-up period and 12% of people randomised to cholecystectomy did not undergo the scheduled operation.

Cost-effectiveness
The results of the economic evaluation showed that, on average, the surgery strategy cost £1236 more than the conservative management strategy but was, on average, more effective, and generated 0.094 additional QALYs. The incremental cost per QALY was £13,205. The result of the incremental cost-effectiveness analysis indicated that the conservative management strategy had a 51% chance of being considered cost-effective when society’s willingness to pay for a QALY was £20,000 and a 46% chance when willingness to pay was £30,000. The probability of cost-effectiveness was not sensitive to changes in the threshold, when the threshold increased to £30,000, the surgery strategy had a 51% chance of being considered cost-effective. The results were sensitive to the probability of people in conservative management undergoing cholecystectomy. An increase in the number of people requiring surgery while treated conservatively corresponded to a reduction in the cost-effectiveness of the conservative strategy. There was uncertainty around the estimate derived from the meta-analysis of clinical effectiveness. On average, the cost of the conservative management strategy was reduced to £694 when the probability of undergoing surgery was reduced to 25%, leading to an incremental cost-effectiveness ratio (ICER) of £33,542 per QALY for the surgical strategy. In contrast, the cost of the conservative management strategy increased to £1757, leading to a reduced ICER of £4291 when the probability of surgery among people initially managed conservatively was increased to 75%.

Strengths and limitations
The methods used to conduct this assessment were detailed and thorough. The main limitation of this assessment was the limited data currently available on the clinical effectiveness and safety of observation/conservative management compared with cholecystectomy for the treatment of uncomplicated symptomatic gallstone disease (biliary pain or cholecystitis) in the UK. The paucity of both utility and clinical effectiveness data added uncertainty to the economic evaluation.
Conclusions

The results of this assessment showed that approximately half of the people in the observation group were eventually operated on. Participants who underwent cholecystectomy experienced more surgery-related complications and showed a slight, non-significant, increase in the rate of all-cause mortality than those who were treated conservatively. In contrast, participants allocated to observation had more episodes of cholecystitis, but few other gallstone-related complications (e.g. common bile duct stones, acute pancreatitis). Approximately half of the people in the observation group did not require surgery in the long term, indicating that there is probably a subgroup of people with uncomplicated symptomatic gallstones who could benefit from conservative management.

Cholecystectomy is more costly to the NHS because of the use of resources associated with surgery and the costs related to the treatment of post-surgery complications. Our modelling shows that conservative management is, on average, less costly but also less clinically effective for the treatment of symptomatic gallstones. A policy of surgery for all, rather than a policy of conservative management followed by surgery among people whose symptoms persist, is likely to be more effective even though more costly. The difference between the two policies, however, is small. Uncertainty in the economic model was mostly driven by the pre- and post-surgery utility values, as well as by the future probability of receiving surgery following a strategy of conservative management.

Recommendations for future research

- A large, well-designed clinical trial needs to be undertaken to compare the effects and safety of observation/conservative management with cholecystectomy in people presenting with uncomplicated symptomatic gallstones (biliary pain) or cholecystitis to secondary care. This trial would contribute to identify factors which may allow the clinicians to single out people who are more likely to benefit from surgery from those at low risk of subsequent events and complications. Ideally, such a trial would include relevant outcome measures, such as post-cholecystectomy symptoms and quality-of-life measurements, and a full economic evaluation.
- Further research to evaluate the natural history of symptomatic gallstone disease (including uncomplicated cases).
- Research to elicit factors that may predict the evolution of symptoms in people with symptomatic gallstone disease.
- Research on people’s personal preferences in terms of treatment options and outcomes.
- Research to identify resource use for people undergoing cholecystectomy (pre-operative assessment, surgical admissions and post-operative management) and for those receiving conservative management, in order to develop more robust cost estimates for the UK.

Study registration

This study is registered as PROSPERO CRD42012002817

Funding

The National Institute for Health Research Health Technology Assessment programme.
Chapter 1  Background

Description of health problem

Introduction

Gallstone disease (cholelithiasis) is one of the most common and costly gastrointestinal disorders in industrialised societies.\(^1\)–\(^4\) The prevalence of gallstones in these adult populations is approximately 10–15\%.\(^1\),\(^5\)–\(^9\) Gallstones are more common in women and people over the age of 40 years.\(^10\)

Approximately 80\% of people with cholelithiasis do not have symptoms,\(^11\),\(^12\) can remain asymptomatic for many years and do not require treatment.\(^13\),\(^14\) About 20\% of people experience pain and clinical complications.\(^1\),\(^5\)–\(^6\),\(^15\)

Surgery remains the treatment of choice for symptomatic gallstones,\(^16\) even though early natural history studies showed that recurrent pain attacks may diminish in up to half of symptomatic people.\(^17\) As many studies have concentrated on the best timing of performing surgery and on operative outcomes and complications, the question whether or not cholecystectomy is always required in people with mild, uncomplicated symptomatic gallstones has not been rigorously evaluated. There is evidence to show that it is feasible to conduct randomised controlled trials (RCTs) to compare the effects and safety of cholecystectomy with those of observation/conservative treatment.\(^18\)

The aim of the present assessment is to evaluate the clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting initially with uncomplicated symptomatic gallstones for whom surgery is considered a treatment option.

Aetiology, pathophysiology and clinical presentation

The gallbladder is a pear-shaped pouch which stores and concentrates bile entering the organ via the hepatic and cystic ducts (Figure 1). The concentrated bile is later ejected into the duodenum in response to food entering the intestines. The gallbladder is located beneath the liver and can hold between 30 and 50 ml of bile. Histologically, the gallbladder wall consists of serous, muscular and mucous layers.\(^19\)

Gallstones are solid accumulations of either cholesterol, mucin, calcium bilirubinate or protein\(^20\) and occur when the constituents come out of solution.\(^21\) Most gallstones (> 80\%) consist largely of cholesterol,\(^7\),\(^22\) whereas pigment stones consist of calcium bilirubinate and mucin glycoproteins. Both types of gallstone form in the gallbladder itself.

Known risk factors for adults with gallstone disease include:\(^8\),\(^23\)

- increasing age
- obesity
- family history of gallstone disease
- ethnicity
- recent weight loss (for example, crash diets or weight-loss surgery)
- digestive disorders (e.g. Crohn’s disease, irritable bowel syndrome)
- cirrhosis
- diabetes.
Women who:

- take oral contraception
- have high-dose oestrogen therapy or
- are pregnant

are at higher risk (twice as likely as men) of developing gallstones. Some risk factors are modifiable, such as diet and obesity, while others are not (e.g. sex, age, concomitant diseases).22

The most relevant symptom of gallstone disease is pain (i.e. biliary colic). Typically, biliary colic is defined as pain, moderate to severe, localised to the right upper quadrant or epigastrium lasting more than half an hour which occasionally can radiate to the right scapula. The pain may be accompanied by nausea and vomiting, may occur post-prandially and may wake the person at night. Although biliary pain is specific to gallstone disease, many people may present with other abdominal symptoms.24 In some people, the symptoms are mild and consist of vague indigestion or dyspepsia. Dyspeptic symptoms (e.g. belching, bloating, heartburn), however, are not specific to gallstone disease.5,7,25

**Epidemiology and prognosis**

Diseases of the gallbladder are widespread, affecting approximately 10–15% of the adult population.26 Clinical surveys conducted in Europe, North and South America and Asia indicate that the prevalence rates for gallstone disease range from 5.9% to 25%27–37 and tend to increase with age. A clinical ultrasound survey conducted in the UK reported prevalence rates of 12% among men and 22% among women over 60 years of age.35 A multicentre, population-based study conducted in Italy has reported a cumulative incidence of gallstone disease of 0.67% per year (0.66% in men and 0.81% in women).38 In the developed world, gallstone disease is the most common gastrointestinal complaint for which people are admitted to hospital.2,10,39 Hospital admissions increased in England by 30% in men and by 64% in women from 1989–90 to 1999–2000.3

Natural history studies have shown low mortality from gallstone disease, with typically < 1% of people dying from gallbladder-related causes.3,12,13,17 The natural course of gallstone disease is benign, with a relatively low progression from asymptomatic disease to symptomatic disease. In a recent population-based study, the overall frequency of symptom development in asymptomatic people was around 20% over a long follow-up period (mean 8.7 years).17 An early natural history study (in which people were found to have gallstones through routine screening), showed that 10%, 15% and 18% of people assessed became symptomatic at 5, 10 and 15 years, respectively.40

![Biliary system](http://www.daviddarling.info/encyclopaedia/G/gall_bladder.html) (last accessed May 2013). Reproduced with permission of David Darling.
Overall, the annual risk of developing complications for people with asymptomatic gallstones is low, about 0.1–0.2%. In contrast, in people with symptomatic gallstone disease, the annual rates of developing complications have been reported to be higher, 1–3%. The Italian Group for the Epidemiology and Prevention of Cholelithiasis study reported an annual incidence of complications of 0.3% for asymptomatic people and 0.7% for symptomatic people. In particular, there is a proportion of people with uncomplicated gallstone disease who may experience only a few episodes of biliary pain without developing serious symptoms or complications for many years. A recent multicentre study found that a considerable proportion of people with mild and severe symptoms (58% and 52%, respectively) did not experience subsequent episodes of biliary pain during the 10-year follow-up period and 10% suffered from gallstone complications, indicating a benign course of the disease even in those with initially severe symptoms. Moreover, the severity of the disease does not seem to increase over time.

In the UK and in North America, the number of surgical procedures for gallstone disease increased steadily between the 1950s and 1990s, reflecting both the rise in prevalence of gallstone disease and the use of cholecystectomy as the treatment of choice. Rates of surgical procedures stabilised in both countries towards the end of the twentieth century.

Impact of health problem

From a patient perspective, the defining symptom of gallstone disease is pain. Commonly, general abdominal symptoms intensify over a period of time and become regular pain attacks, which require medical attention. Although the pain experienced may be described as ‘non-specific’, it tends to occur in a defined location and with characteristic patterns as described above. Best medical therapy includes the prescription of analgesics and, when necessary, antibiotics.

The most common complications associated with gallstones are acute cholecystitis, common bile duct (CBD) stones and acute pancreatitis. Acute cholecystitis is caused by a gallstone obstructing the cystic duct and results in unresolving upper right quadrant pain, nausea, vomiting, anorexia and fever. CBD stones are found in up to 15% of people who undergo cholecystectomy. They may be asymptomatic or accompanied by biliary pain, jaundice, pancreatitis or cholangitis. CBD stones can cause acute pancreatitis by obstructing the main pancreatic duct. The typical symptoms of gallstone-related pancreatitis are epigastric abdominal pain, nausea and vomiting. Pancreatitis is severe in over 20% of people with gallstone disease and can cause death in about one-third.

Even though removal of the gallbladder is considered the standard treatment for symptomatic gallstones, it does not guarantee eradication of symptoms. Up to approximately 40% of people may continue to experience pain and abdominal symptoms after surgery. In particular, marked biliary pain has been described in 4–9% of people after cholecystectomy, while persistent abdominal pain or non-specific pain persists in about 13–37% of people. A recent systematic review of the literature found that up to one-third of people suffered continuing pain after cholecystectomy and up to 14% of people experienced de novo pain. Some investigators have also reported a persistent pain similar to that experienced pre-operatively in about 20% of people with gallstones. In a prospective study conducted in Denmark, 21% of people experienced the same type of pain after surgery. Similarly, in a RCT conducted in the UK, 19% of people complained of biliary pain 5 years after open cholecystectomy. No difference has been observed between open and laparoscopic surgery in terms of persistent pain. The term ‘post-cholecystectomy syndrome’ is an umbrella term that has been widely used to describe, though not accurately, the range of symptoms which occur after cholecystectomy. The term ‘persistent post-cholecystectomy symptoms’ has been suggested as a more accurate description of these symptoms. These symptoms include biliary and non-biliary abdominal pain, gastrointestinal disorders, dyspepsia, heartburn, nausea, vomiting, jaundice and cholangitis. Severe symptoms which occur early after surgery may represent complications of cholecystectomy, whereas those that manifest later (after months or years) are probably unrelated to cholecystectomy and explained by non-biliary causes. Non-biliary causes are more likely if the symptoms are similar to those experienced pre-operatively and no stones are found in the gallbladder. Recent research has suggested that, in some people, functional gastrointestinal disorders...
and not gallstone disease may be the cause of persistent post-surgery symptoms. Nevertheless, there is no consistent pathophysiological explanation for persistent post-cholecystectomy symptoms, and in about 5% of people the reason for persistent abdominal pain remains unknown.

**Current service provision**

**Management of disease**

Management of gallstone disease may include pharmacological, non-pharmacological and surgical interventions. Surgery is the definitive way to treat gallstone disease. Laparoscopic cholecystectomy is currently preferred over open cholecystectomy for elective surgery in symptomatic gallstones. In the UK, people with biliary pain are commonly put on a waiting list and undergo elective surgery several months after the original clinical diagnosis, although early and urgent surgery during the same admission is becoming more common.

People with symptomatic gallstones who are unfit or unwilling to undergo surgery are managed conservatively or may be offered alternative non-surgical treatments. In particular, conservative management is a feasible and relatively safe option for pregnant women and elderly people who are less likely to tolerate surgery. The terms ‘observation’ and ‘conservative management’ are not clearly defined in the current literature and appear to be used interchangeably. In general, observation/conservative management in the context of gallstone disease involves the prescription of analgesics to relieve the biliary pain. Typical therapy includes narcotic analgesics (e.g. opiates) or non-steroidal anti-inflammatory drugs (e.g. ibuprofen) together with generic lifestyle advice. Complicated biliary pain (i.e. inflammation of the gallbladder, namely acute cholecystitis) usually requires additional therapy with antibiotics.

Medical therapy for gallstone disease using bile acids, for example ursodeoxycholic acid, to dissolve stones (especially cholesterol stones) is presently restricted to a small, highly selected group of symptomatic people for whom a surgical intervention is not recommended and recurrence is likely to have particularly adverse consequences. Novel experimental animal models and preliminary clinical findings indicate that future research could focus on the mechanisms of intestinal absorption of cholesterol, on hepatic cholesterol biosynthesis as well as on the role of gallstones genes.

Other non-pharmacological, non-surgical treatments include dissolution/fragmentation of gallstones using the cholesterol solvent methyl tert-butyl ether (MTBE) and extracorporeal shock wave lithotripsy (ESWL). These treatment options are very rarely used in clinical practice because of their potential side effects (MTBE), high recurrence rate in people with multiple stones (ESWL) and occurrence of transient biliary pain after successful stone fragmentation (ESWL).

The widespread use of laparoscopic cholecystectomy together with the use of imaging techniques for a more accurate diagnosis of symptomatic gallstone disease has contributed to the decline in non-surgical medical interventions such as oral bile acids and ESWL.

**Current service cost**

Even though the majority of gallstones are asymptomatic and do not require treatment, gallstone disease is still the most expensive of the digestive disorders in industrialised societies. Considerable resources are involved in managing people with symptomatic gallstones. The bulk of the economic burden is mainly due to the costs associated with surgery for the removal of the gallbladder.

According to the NHS 2011/12 tariff for admitted patient care and outpatients procedures, for laparoscopic cholecystectomy, the day case tariff was £1689, whereas the elective spell tariff was £1370 and the non-elective spell tariff £3197. For open cholecystectomy, the combined day case and spell tariff
was £2285, whereas the non-elective spell tariff was £4513.84 Best practice tariffs were introduced in England in 2010–11 to incentivise cholecystectomy on a day-case basis, where clinically appropriate.

**Variation in services and/or uncertainty about best practice**

In the UK, people with biliary pain are usually put on a waiting list and undergo elective surgery several months after establishment of a clinical diagnosis of gallstone disease. The waiting time for elective cholecystectomy varies from hospital to hospital depending on the resources available, but generally lies between 4 and 12 months (although current clinical targets have led to a shortening of waiting lists). There is a marked variation between UK health trusts in terms of rates for laparoscopic cholecystectomy. Approximately half of trusts perform < 5% of cholecystectomies as day cases, with many trusts performing no day procedures at all. The variation is likely to be explained by the local resources available in each trust and the number of people with symptomatic gallstone disease being treated during the same emergency admission or electively after undergoing a period of conservative treatment.

**Relevant national guidelines, including National Service Frameworks**

There are no current published national guidelines on the management of gallstone disease.

**Description of technologies under assessment**

**Summary of the surgical procedures under assessment**

Laparoscopic cholecystectomy is the current standard surgical procedure for the management of gallstone disease. Since its development in the late 1980s, laparoscopic cholecystectomy has increasingly replaced open cholecystectomy, which remained the gold standard surgical treatment for over 100 years. Laparoscopic cholecystectomy has been demonstrated to be a safe and cost-effective procedure with similar mortality and complications rates to those of open cholecystectomy, but significant shorter hospital stay, quicker recovery and lower total cost.

**Open cholecystectomy**

The first open cholecystectomy was performed in 1882 by Carl Langebuch. After making an open incision, the peritoneum covering the triangle of Calot (the area bound by the inferior border of the liver, cystic duct and common hepatic duct) is dissected, permitting the cystic artery and duct to be identified then ligated and divided. The gallbladder can then be dissected from the liver bed (either from the infundibulum up or from the fundus down). The standard post-operative course is about 5 days as an inpatient, followed by 3–6 weeks' convalescence, and remains significantly longer than laparoscopic cholecystectomy.

With the widespread use of laparoscopic procedures, there are now limited indications for initiating a cholecystectomy as an open procedure. Nowadays, the majority of open cholecystectomies consist of conversions from laparoscopic procedures. Conversion to an open procedure may be required because of the presence of adhesions, difficulty in delineating the anatomy or a suspected complication. Conversion is needed more often in those with prior abdominal surgery, acute cholecystitis or severe/advanced diseases. Conversion rates are typically < 10%, including emergency procedures.

**Laparoscopic cholecystectomy**

The majority of people with symptomatic gallstones are candidates for laparoscopic cholecystectomy unless they are unable to tolerate a general anaesthetic or have comorbidities that preclude surgery.

During laparoscopic cholecystectomy, the person is placed in the supine position on the operating table and anaesthetised. Access to the abdomen is gained by either a Veress needle, the open Hasson technique (direct trocar placement without prior pneumoperitoneum) or the optical view technique (in which the laparoscope is inside the trocar to allow the abdominal wall layers to be visualised as they are crossed). The surgeon inflates the abdominal cavity with carbon dioxide to create a working space. The camera is placed...
through the umbilical port and the abdominal cavity is inspected. Additional ports are inserted to allow the insertion of instruments. The gallbladder fundus is identified, grasped and retracted superiorly. With a second grasper, the gallbladder infundibulum is retracted laterally to expose and open Calot’s triangle. The cystic duct and the cystic artery are identified, clipped and divided. The gallbladder is then dissected from the liver bed and removed via the umbilical port or the epigastric port. Laparoscopic surgery requires meticulous and specific surgical skills. The procedure usually results in shorter hospital admission and recovery period than open cholecystectomy (1–2 days in hospital and 1–2 weeks of convalescence).

The National Institute of Health Consensus Conference statement concluded that laparoscopic cholecystectomy provides a safe and effective treatment for most people with symptomatic gallstones.

A Cochrane systematic review comparing open cholecystectomy with laparoscopic cholecystectomy for symptomatic gallstones demonstrated similar mortality and complications rates between the two procedures but shorter hospital stay, recovery period and lower total cost for laparoscopic surgery.

Single-incision laparoscopic cholecystectomy
Laparoscopic cholecystectomy typically results in three or four small scars caused by the port sites, which is a marked improvement over the scars left by open procedures. However, there have been recent efforts to further reduce the potential for scarring by the introduction of the so-called single-incision laparoscopic procedure. The laparoscope and instruments are both inserted using a single port in the umbilicus, a location in which a scar can effectively be camouflaged. From a technical point of view, the single-incision laparoscopic procedure is very similar to standard laparoscopic cholecystectomy.

Several recent systematic reviews have compared single-incision and conventional laparoscopic cholecystectomy. Arezzo and colleagues concluded that the single-incision approach was not associated with more complications than the conventional laparoscopic approach. In addition, no mortality was reported and conversion rates to open cholecystectomy were similar for both procedures. Wang and colleagues found a higher conversion rate for single-incision cholecystectomy, but did not observe any difference in complication rates between single-incision and conventional laparoscopic surgery. Antoniou and colleagues observed higher complication rates for people over 45 years of age.

In a recent Cochrane systematic review comparing open cholecystectomy with small incision (< 8 cm) cholecystectomy for symptomatic gallstones, no differences were observed between the two surgical procedures with regard to complications and mortality rates. Hospital stay was, however, significantly shorter for small incision cholecystectomy.

Current usage in the National Health Service
At present, the definitive treatment choice for gallstone disease is surgery. Cholecystectomy is one of the most common surgical procedures performed in the UK. About 70,000 cholecystectomies were performed in England between 2011 and 2012. The majority of these surgical procedures were performed after an elective admission and undertaken laparoscopically. Laparoscopic cholecystectomy is technically more challenging to perform than the traditional open cholecystectomy and the success of the operation depends on the experience, specialisation and technical skills of the surgeon who performs the procedure. In Scotland, the total cholecystectomy rate increased by 18.7% between 1989 and 1993. Hospital Episode Statistics data for England for 2011–12 reported 65,926 admissions for excision of the gallbladder with a mean waiting time of 81 days. There were 6148 (9%) emergency admissions and 57,920 (88%) on the waiting list.

While waiting for surgery, people with symptomatic gallstones are treated conservatively. People who are unfit or unwilling to undergo surgery are managed by means of a ‘wait and see’ therapeutic strategy. Similarly, people with a single episode of biliary pain and no complications of gallstone disease may be potential candidates for conservative management, with a reasonable chance to remain symptom free.
Chapter 2 Definition of the decision problem

Decision problem

The purpose of this assessment was to evaluate the clinical effectiveness and the cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with first episode of symptomatic gallstones in secondary care. The summary care pathway illustrating the decision problem addressed in this assessment is shown in Figure 2. The care pathway was developed using available published evidence, as well as the outcome of two advisory meetings with clinical experts convened for the purpose of this assessment. Although the pathway was primarily designed to guide the main phases of this assessment (e.g. gathering of existing evidence, development of an economic model), it is broadly consistent with previously published algorithms for the management of gallstone disease. This chapter will consider the main components of the care pathway for gallstone disease. Specific information on the population, intervention, comparator and relevant outcomes considered for this assessment will be provided in Chapter 3 (Methods of the systematic review of clinical effectiveness).

Population

The population considered for this assessment is adults with symptomatic uncomplicated gallstone disease (biliary pain or acute cholecystitis) who are examined in a secondary care setting and considered suitable for cholecystectomy.

Clinical diagnosis of gallstone disease is usually confirmed by imaging and laboratory tests. Transabdominal ultrasonography is the standard imaging technique for the diagnosis of gallbladder stones. The technique is accurate, non-invasive and very widely available.

Intervention: cholecystectomy

Cholecystectomy is the standard treatment for symptomatic gallstone disease and its frequency is increasing worldwide. Nowadays, nearly all cholecystectomies in the UK are performed using a minimally invasive laparoscopic approach (laparoscopic cholecystectomy). Any cholecystectomies performed openly or laparoscopically (or variants thereof) are considered suitable for inclusion.

Comparator: observation/conservative management

The comparator intervention considered in this assessment is observation/conservative management. ‘Conservative management’ in the context of gallstone disease typically comprises the prescription of analgesics/anti-inflammatory drugs along with lifestyle advice. People with cholecystitis and signs of inflammation are usually prescribed antibiotics.

‘Delayed surgery’ is not considered a suitable comparator. The focus of recently published randomised trials and meta-analyses looking at early compared with delayed cholecystectomy (open and laparoscopic) has been on the optimal timing of surgical intervention as well as operative outcomes (in a patient population scheduled to receive surgery) rather than on the necessity of cholecystectomy in people with uncomplicated symptomatic gallstones presenting to secondary care.
Overall aims and objectives of assessment

The aim of this assessment was to evaluate the clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with symptomatic gallstones (biliary pain or cholecystitis) in secondary care for the first time.

The specific objectives of this assessment will help to facilitate decision-making on the most appropriate treatments for people suffering from uncomplicated symptomatic gallstone disease (biliary pain or cholecystitis) by:

- conducting a systematic review of the evidence available on the clinical effectiveness of cholecystectomy compared with observation/conservative management
- conducting a systematic review of the evidence available on the cost-effectiveness of cholecystectomy compared with observation/conservative management
- developing an economic model to compare the cost-effectiveness cholecystectomy with that of observation/conservative management
- determining which management options are most likely to be efficient for implementation into the UK NHS
- identifying and prioritising future research.
Chapter 3 Methods of the systematic review of clinical effectiveness

The methods for this assessment were pre-specified in a protocol.

Identification of studies

Comprehensive literature searches were conducted to identify reports of studies on the clinical effectiveness and/or cost-effectiveness of cholecystectomy compared with non-surgical interventions for the management of people with symptomatic gallstone disease (biliary pain or acute cholecystitis). Highly sensitive search strategies were designed, including appropriate subject headings and free-text terms for the interventions under consideration and relevant study designs. No language restrictions were imposed on the literature searches. Searches were restricted to 1980 onwards, to mirror the use of surgical techniques currently available in clinical practice as well as the introduction of novel interventions for the management of symptomatic gallstones.

Databases searched were MEDLINE (1980 to 9 September 2012), MEDLINE In-Process & Other Non-Indexed Citations (10 September 2012), EMBASE (1980 to 10 September 2012), the Science Citation Index (1980 to 12 September 2012), Bioscience Information Service (BIOSIS; 1980 to 12 September 2012) and the Cochrane Central Register of Controlled Trials (date of inception to Issue 9, 2012). Reports of relevant evidence syntheses were also sought from the Cochrane Database of Systematic Reviews and the Database of Abstracts of Review of Effects.

The World Health Organization International Clinical Trials Registry (date of inception to September 2012), Current Controlled Trials (date of inception to September 2012), Clinical Trials (date of inception to September 2012) and the National Institute for Health Research Portfolio (date of inception to September 2012) were also searched to identify potential relevant ongoing studies. Conference proceedings from 2011 and 2012 of key organisations such as the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the Association of Laparoscopic Surgeons of Great Britain and Ireland and the British Society of Gastroenterology were screened for further relevant reports. The reference lists of all included studies were perused to identify additional potentially relevant reports. Full details of the search strategy are reported in Appendix 1.

Inclusion and exclusion criteria

Types of studies

For assessing the clinical effectiveness of cholecystectomy compared with observation/conservative management in people with biliary pain or acute cholecystitis, the following types of study design were deemed suitable for inclusion:

- RCTs which randomised people to either cholecystectomy (open or laparoscopic) or observation/conservative management, irrespective of study language, blinding and publication status
- non-randomised comparative studies in which people received either cholecystectomy (open or laparoscopic) or observation/conservative management.
The following types of report were excluded:

- reviews, editorials and opinions
- case series and case reports
- reports published in non-English languages for which a translation could not be organised.

**Types of participants**

Adults (18 years and older or ‘adults’ as defined by the triallists) with symptomatic gallstone disease (biliary pain or acute cholecystitis) being considered for cholecystectomy in a secondary care setting for the first time. Gallstone-related disease needed to be confirmed by ultrasonography. For the purpose of this assessment, ‘first episode of symptomatic gallstones’ was defined as the first instance in which the patient presented to secondary care attention (with the possibility of receiving surgical treatment) even though the clinical history documented previous clinical symptoms or pain attacks. This criterion was later relaxed to allow inclusion of studies in which up to 25% of participants had previously presented to secondary care for symptomatic gallstones. First episode was assumed unless studies explicitly described cases as recurrent. Eligibility for cholecystectomy, if not explicitly reported, was assumed in RCTs whereas non-randomised studies were assessed on an individual basis on this criterion. An accepted definition of ‘acute cholecystitis’ is based on a combination of relevant clinical symptoms (e.g. pain localised to the right upper quadrant of the abdomen; temperature exceeding 37.5 °C, leucocytosis greater than 10 x 10⁹/l, increased C-reactive protein level) and ultrasonographic evidence of gallstones.

People with acute severe cholecystitis (e.g. obstruction of the cystic duct or neck of the gallbladder by gallstones) and/or cholangitis (inflammation, usually infection, of a bile duct) or pancreatitis were not considered suitable for inclusion, as they normally require urgent or emergency intervention. Similarly, people with symptomatic gallstones complicated by severe concomitant diseases, critically ill people, and/or people who were judged to be unfit or unsuitable for surgery (e.g. pregnant women) were not considered within the scope of this review.

Therefore, for those with acute cholecystitis, we included any study population presenting with acute, uncomplicated, cholecystitis.

**Intervention**

The intervention considered was surgical removal of the gallbladder (laparoscopic or open cholecystectomy).

**Comparator interventions**

The comparator interventions considered were observation (watchful waiting) and/or conservative treatment. Conservative treatment refers here to a course of analgesics/anti-inflammatory drugs accompanied by lifestyle advice. People with cholecystitis and signs of inflammation may also be prescribed antibiotics.

**Types of outcomes**

The following types of outcome measure were considered:

- disease-related morbidity
  - recurrence of symptoms
  - complications (e.g. pancreatitis)
  - number of visits to primary care settings or hospital emergency department
  - analgesic requirements
  - need for surgical, endoscopic or radiological intervention
  - need for further medical intervention
  - mortality
• surgery-related morbidity
  - bile duct injury
  - infection/bleeding
  - reoperation rate
  - diarrhoea
  - recurrent pain
  - mortality
• patient-driven outcomes
  - generic and disease-specific quality of life (QoL; as defined by the studies’ authors)
• cost of initial and any subsequent treatments.

Data extraction strategy

One reviewer (MC) screened all titles and, when available, abstracts of all citations identified by the search strategies. All potentially relevant reports were retrieved in full and assessed independently by two reviewers. Any disagreements were resolved by consensus or referred to a third party. A sample full-text screening form is presented in Appendix 2.

A data extraction form was designed specifically for the purpose of this assessment to collect data from included studies. Two independent reviewers (MC and MB) extracted details of study design, characteristics of participants, characteristics of interventions and outcome measures. Any disagreements were resolved by consensus. A sample data extraction form is presented in Appendix 3.

Critical appraisal strategy

Included RCTs were assessed by means of the Cochrane Collaboration’s risk of bias tool.112 A sample form is presented in Appendix 4. Two reviewers (MC and MB) independently assessed the risk of bias within each included trial based on the following domains: sequence generation, allocation concealment, blinding, incomplete outcome data and selective outcome reporting. Individual outcomes were categorised as high risk of bias, low risk of bias or unclear risk of bias. Any disagreements between reviewers were resolved by consensus.

Methods of data synthesis

Results of each included study were tabulated for all outcomes with means reported for continuous outcomes and proportions for dichotomous outcomes. Where the same outcome was assessed by more than one included study, a quantitative synthesis of results was carried out using Review Manager (RevMan) computer program (version 5.2. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012). Heterogeneity between studies was assessed by visual inspection of forest plots and from Mantel–Haenszel chi-squared and $I^2$ tests. Meta-analyses using the Mantel–Haenszel method were carried out to estimate risk ratios pooled across studies, with corresponding 95% confidence intervals (CIs). Where there was unacceptable heterogeneity between studies, random-effects models were used, otherwise fixed-effects models were applied.
Chapter 4 Clinical effectiveness of cholecystectomy compared with observation/conservative management

Quantity of research available

Number and type of studies included
The primary literature searches identified 6779 potentially relevant citations. Seventy-seven reports were selected for full-text assessment. Seventy-one reports were subsequently excluded (see Appendix 5). Two RCTs published in six reports were included in this assessment.46,55,77,78,113,114 No eligible non-randomised comparative studies were identified by the literature searches. A flow diagram of the screening process is outlined in Figure 3.

Appendix 5 provides the bibliographic details of the included and excluded studies.

Number and type of studies excluded
A list of the 71 full-text papers that were excluded along with the reasons for their exclusion is given in Appendix 5. These reports were excluded because they failed to meet one or more of the inclusion criteria in terms of the type of study, participants, intervention/comparator or outcomes reported.

Characteristics of the included studies
The search identified two randomised trials, Schmidt et al.113 and Schmidt et al.,46 published in full in six reports.46,55,77,78,113,114 Participants were enrolled consecutively in both trials and data were collected prospectively. Both trials were conducted in Norway.

Table 1 presents the demographic information from the studies. The two trials included a total of 201 participants at enrolment. There were no dropouts during the study period and all 201 randomised participants were included in the statistical analyses. Participants’ diagnosis was uncomplicated symptomatic gallstones (biliary pain only) in Schmidt et al.113 and acute cholecystitis in Schmidt et al.46 In total, 149 women and 52 men were assessed. Of these, 72 women and 27 men were randomised to surgery, while 77 women and 25 men were randomised to observation. Median age was 50 years (range 20–79 years) in Schmidt et al.113 and 58 years (range 27–77 years) in Schmidt et al.46 Both trials enrolled some participants who had previously presented to secondary care for gallstone disease: 30 participants (22%) in Schmidt et al.113 and 11 participants (17%) in Schmidt et al.46 Both trials also reported the number of participants with concomitant diseases, specifically heart disease, diabetes and/or obstructive lung disease, in total 16 participants (12%) in Schmidt et al.113 and 12 participants (19%) in Schmidt et al.46 Baseline QoL, as assessed by the psychological general well being index (PGWB), Nottingham Health Profile (NHP) part II, pain score and Visual Analogue Pain Score (VAPS), were comparable across the studies. The mean follow-up was 14 years (range 13–16 years) for both trials. Similarly, the median follow-up was 14 years in Schmidt et al.46

Table 2 presents the key features of the two included studies.
Studies identified from primary searches \((n=6\,779)\)

Excluded \((n=6\,622)\)

Excluded \((n=71)\)
1 no relevant outcomes
13 ineligible study design
17 ineligible population
33 ineligible comparator
7 unavailable

Included \((n=2; 6\ reports)\)

Studies identified from other sources \((n=1)\)

Retrieved for background \((n=48)\)

Retrieved for cost-effectiveness review \((n=33)\)

Selected for full-text screening \((n=77)\)

FIGURE 3 Flow chart for the identification and selection of studies.
### TABLE 1  Demographic information of included studies

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Surgery (n = 68)</td>
<td>Observation (n = 69)</td>
</tr>
<tr>
<td></td>
<td>Surgery (n = 31)</td>
<td>Observation (n = 33)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (%)</td>
<td>13 (19)</td>
<td>12 (17)</td>
</tr>
<tr>
<td></td>
<td>14 (45)</td>
<td>13 (39)</td>
</tr>
<tr>
<td>Women (%)</td>
<td>55 (81)</td>
<td>57 (83)</td>
</tr>
<tr>
<td></td>
<td>17 (55)</td>
<td>20 (61)</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (median, range)</td>
<td>52 (27–74)</td>
<td>60 (30–79)</td>
</tr>
<tr>
<td></td>
<td>64 (41–77)</td>
<td>64 (29–73)</td>
</tr>
<tr>
<td>Women (median, range)</td>
<td>52 (20–77)</td>
<td>48 (22–75)</td>
</tr>
<tr>
<td></td>
<td>58 (27–77)</td>
<td>47 (29–71)</td>
</tr>
<tr>
<td>Age overall (median, range)</td>
<td>50 (20–79)</td>
<td>58 (27–77)</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td>Uncomplicated symptomatic gallstones (biliary pain only)</td>
<td>Acute cholecystitis</td>
</tr>
<tr>
<td>Previous gallstones attacks (%)</td>
<td>64 (94)</td>
<td>63 (91)</td>
</tr>
<tr>
<td></td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Previous hospitalisation for gallstone disease (%)</td>
<td>14 (21)</td>
<td>16 (23)</td>
</tr>
<tr>
<td></td>
<td>11 (17)</td>
<td>NR</td>
</tr>
<tr>
<td>Concomitant disease (heart disease/diabetes/ obstructive lung disease) (%)</td>
<td>16 (12)</td>
<td>12 (19)</td>
</tr>
<tr>
<td><strong>Baseline QoL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGWB score (higher score better)</td>
<td>93.7 (n = 63)</td>
<td>95.2 (n = 67)</td>
</tr>
<tr>
<td></td>
<td>88.1 (n = 31)</td>
<td>94.2 (n = 31)</td>
</tr>
<tr>
<td>NHP score (lower score better)</td>
<td>2.0 (n = 50)</td>
<td>1.8 (n = 53)</td>
</tr>
<tr>
<td></td>
<td>2.2 (n = 28)</td>
<td>2.0 (n = 29)</td>
</tr>
<tr>
<td>Pain score (lower score better)</td>
<td>6.3 (n = 67)</td>
<td>6.7 (n = 66)</td>
</tr>
<tr>
<td></td>
<td>8.1 (n = 31)</td>
<td>6.6 (n = 33)</td>
</tr>
<tr>
<td>VAPS (lower score better)</td>
<td>47.2 (n = 67)</td>
<td>48.1 (n = 65)</td>
</tr>
<tr>
<td></td>
<td>57.7 (n = 31)</td>
<td>57.1 (n = 31)</td>
</tr>
</tbody>
</table>

NHP, Nottingham Health Profile part II, range 0–7; pain score, encompasses intensity and duration of pain in the last week; frequency of pain and analgesic use in last 6 months, range 0–16; NR, not reported; PGWB, Psychological General Well Being index, range 22–132; VAPS, Visual Analogue Pain Score, people mark a non-graded 100-mm line ranging from no pain to unbearable pain to reflect intensity of pain during previous week.
### TABLE 2 Key features of included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Geographical location</th>
<th>Source of funding</th>
<th>No. of participants randomised</th>
<th>Diagnosis</th>
<th>Primary outcomes (patient level)</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmidt et al. 2011&lt;sup&gt;113&lt;/sup&gt; (Vethus et al. 2002, Vethus et al. 2004)&lt;sup&gt;23,13&lt;/sup&gt;</td>
<td>Norway</td>
<td>Research Council of Norway; Research Committee of Rogaland Central Hospital; University of Bergen; Helga Semb’s Foundation; Karla and Arne Oddmar's Foundation; Haraldsplass Deaconal Hospital and the Western Norway Regional Health Authority through the Centre for Clinical Research at Haukeland University Hospital</td>
<td>Total number randomised: 137 Randomised to observation: 69 Randomised to surgery: 68</td>
<td>Uncomplicated symptomatic gallstones (biliary pain only) Symptomatic gallstone disease was defined as episodes of pain, commonly continuous, in the right subcostal or midline epigastric area, lasting more than 30 minutes with ultrasonographic signs of gallstones and no clinical or laboratory indication of other causes of the symptoms</td>
<td>- Pain attacks&lt;br&gt;- Admission due to gallstone-related pain&lt;br&gt;- Gallstone-related complications&lt;br&gt;- Further medical intervention needed&lt;br&gt;- Surgery-related complications&lt;br&gt;- People requiring surgery (observation group only),&lt;br&gt;- Mortality (due to gallstone disease)&lt;br&gt;- Other causes of mortality</td>
<td>People with uncomplicated symptomatic gallstone disease</td>
<td>Age &lt; 18 years or &gt; 80 years&lt;br&gt;Pregnancy&lt;br&gt;Serious concomitant disease&lt;br&gt;Suspected common bile duct stone&lt;br&gt;People with infrequent and/or minimal pain needing only very occasional medication&lt;br&gt;People with dyspeptic symptoms only</td>
</tr>
<tr>
<td>Study</td>
<td>Geographical location</td>
<td>Source of funding</td>
<td>No. of participants randomised</td>
<td>Diagnosis</td>
<td>Primary outcomes (patient level)</td>
<td>Inclusion criteria</td>
<td>Exclusion criteria</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| Schmidt et al. 2011    | Norway                | Norway; Research Committee of Stavanger University Hospital; University of Bergen; Helga Semb's Foundation; Karla and Arne Oddmar's Foundation; Haraldsplass Deaconal Hospital and the Western Norway Regional Health Authority through the Centre for Clinical Research at Haukeland University Hospital | Total number randomised: 64 | Acute cholecystitis was defined as acute abdominal pain, commonly in the right subcostal or midline epigastric area with a duration of > 8 hours and tenderness on clinical examination in the upper right quadrant. This was confirmed by the presence of gallbladder stones and inflammation signs on ultrasonography and by clinical biochemistry data | • Pain attacks  
• Admission due to gallstone-related pain  
• Gallstone-related complications  
• Surgery-related complications  
• People requiring surgery (observation group only)  
• Mortality (due to gallstone disease)  
• Other causes mortality | People with AC                                                                 | Age < 18 years or > 80 years; severe concomitant disease; suspected common bile duct stone; acalculous cholecystitis; localised peritonitis suggesting gallbladder perforation or gangrenous cholecystitis; people’s preferences; people who needed urgent treatment with surgery or percutaneous management |

AC, acute cholecystitis.
Risk of bias of the included studies
The two published trials were assessed using The Cochrane Collaboration’s risk of bias tool.\textsuperscript{112} \textit{Tables 3 and 4 and Figures 4 and 5} present the summary findings of this assessment. Both trials were judged to be at low risk for all domains assessed by the tool.

\textbf{TABLE 3} Risk of bias table (Schmidt et al. 2011)\textsuperscript{113}

<table>
<thead>
<tr>
<th>Schmidt et al. 2011</th>
<th>Judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low</td>
<td>Randomisation was by a computer program</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low</td>
<td>Brown, opaque, sealed envelopes were used to conceal the allocation</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low</td>
<td>Blinding was not an option, as the intervention being delivered would have been obvious to all concerned</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low</td>
<td>Blinding was not possible as outcomes were either participants’ self-reports or retrieved from medical records</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low</td>
<td>Details of exclusions and attrition were fully reported. All participants were included in the analysis</td>
</tr>
<tr>
<td>Selective reporting (attrition bias)</td>
<td>Low</td>
<td>All stated outcomes were reported</td>
</tr>
<tr>
<td>Other sources of bias (reporting bias)</td>
<td>Low</td>
<td>No other potential sources of bias were identified</td>
</tr>
</tbody>
</table>

\textbf{TABLE 4} Risk of bias table (Schmidt et al. 2011)\textsuperscript{46}

<table>
<thead>
<tr>
<th>Schmidt et al. 2011</th>
<th>Judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low</td>
<td>Randomisation was by a computer program</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low</td>
<td>Brown, opaque, sealed envelopes were used to conceal the allocation</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low</td>
<td>Blinding was not an option, as the intervention being delivered would have been obvious to all concerned</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low</td>
<td>Blinding was not possible as outcomes were either participants’ self-reports or retrieved from medical records</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low</td>
<td>Details of exclusions and attrition were fully reported. All participants were included in the analysis</td>
</tr>
<tr>
<td>Selective reporting (attrition bias)</td>
<td>Low</td>
<td>All stated outcomes were reported</td>
</tr>
<tr>
<td>Other sources of bias (reporting bias)</td>
<td>Low</td>
<td>No other potential sources of bias were identified</td>
</tr>
</tbody>
</table>

\textbf{FIGURE 4} Risk of bias graph for both included studies.
Assessment of clinical effectiveness

A detailed description of the main clinical findings of Schmidt et al.\textsuperscript{113} and Schmidt et al.\textsuperscript{46} is given in Table 5. Meta-analyses of relevant clinical results were performed, when possible. Fixed-effects models were used only where there were acceptable levels of homogeneity between the studies (as identified by visual inspection of forest plots and from Mantel–Haenszel chi-squared and $I^2$ tests), otherwise random-effects models were preferred.

Overview of outcomes included in meta-analyses

Number of participants undergoing surgery (14 years)

A total of 46 out of 102 (45\%) participants randomised to observation and 87 out of 99 (88\%) participants randomised to surgery underwent cholecystectomy (Figure 6). This was a statistically significant difference between the groups (risk ratio $= 0.50$; 95\% CI 0.34 to 0.73; $p = 0.0004$).

Pain attacks (14 years)

A total of 26 out of 102 (25\%) participants randomised to observation and 12 out of 99 (12\%) participants randomised to surgery experienced pain attacks (Figure 7). The difference between the groups was not statistically significant (risk ratio $= 1.62$; 95\% CI 0.43 to 6.17; $p = 0.48$).

In general, pain attacks were reported more frequently in participants with uncomplicated symptomatic gallstone disease managed conservatively. One-third (33\%) of participants with uncomplicated symptomatic gallstones (biliary pain only) randomised to observation experienced pain attacks after randomisation compared with only 9\% of participants with acute cholecystitis. It is worth pointing out that a similar proportion of participants randomised to surgery experienced post-randomisation pain attacks across the groups (12\%, Schmidt et al.;\textsuperscript{113} 13\%, Schmidt et al.\textsuperscript{46}). Significantly more participants with uncomplicated symptomatic gallstones (biliary pain only) randomised to observation experienced pain attacks than those randomised to surgery ($\chi^2 = 9.10; p = 0.0026$), whereas no difference was observed between intervention groups within participants with an initial diagnosis of acute cholecystitis ($\chi^2 = 0.24; p = 0.6253$).
<table>
<thead>
<tr>
<th>Outcomes and adverse events</th>
<th>Schmidt et al. 2011(11) ((n = 137))</th>
<th>Schmidt et al. 2011(11) ((n = 64))</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Observation ((n = 69))</td>
<td>Surgery ((n = 68))</td>
</tr>
<tr>
<td></td>
<td>5 years</td>
<td>14 years</td>
</tr>
<tr>
<td>No. patients undergoing surgery (%)</td>
<td>35 (51)</td>
<td>35 (51)</td>
</tr>
<tr>
<td>Pain attacks*</td>
<td>NR</td>
<td>23 (33)</td>
</tr>
<tr>
<td>Gallstone-related complications (%)</td>
<td>3 (4)</td>
<td>3 (4)</td>
</tr>
<tr>
<td>Acute cholecystitis</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>CBD stones</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Acute pancreatitis</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Surgery-related complications (%)</td>
<td>5 (7)</td>
<td>NR</td>
</tr>
<tr>
<td>Intra-abdominal infection/bile leakage</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Wound infection/dehiscence</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Bile duct injury</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Reoperation</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Minor complications</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Admission due to gallstone-related pain* (%)</td>
<td>12 (17)</td>
<td>NR</td>
</tr>
<tr>
<td>Mortality (%)</td>
<td>NR(^{1})</td>
<td>8 (12)</td>
</tr>
<tr>
<td>Further surgical intervention needed</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Median time to surgery (months) from randomisation (range)</td>
<td>NR</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^{1}\) NR = not reported.
### Outcomes and adverse events

**Schmidt et al. 2011**

<table>
<thead>
<tr>
<th>Outcomes and adverse events</th>
<th>Observation (n = 69)</th>
<th>Surgery (n = 68)</th>
<th>Observation (n = 33)</th>
<th>Surgery (n = 31)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>QoL (mean values) – 6 months</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGWB score (higher score better)</td>
<td>99.9 (n = 59) NR</td>
<td>103.3 (n = 54) NR</td>
<td>110.2 (n = 33) NR</td>
<td>106.2 (n = 25) NR</td>
</tr>
<tr>
<td>NHP score (lower score better)</td>
<td>1.6 (n = 46)</td>
<td>1.1 (n = 43)</td>
<td>1.1 (n = 25)</td>
<td>1.2 (n = 18)</td>
</tr>
<tr>
<td>Pain score (lower score better)</td>
<td>4.1 (n = 63)</td>
<td>2.2 (n = 57)</td>
<td>2.1 (n = 31)</td>
<td>2.0 (n = 27)</td>
</tr>
<tr>
<td>VAPS (lower score better)</td>
<td>14.7 (n = 61)</td>
<td>9.4 (n = 57)</td>
<td>8.1 (n = 30)</td>
<td>5.4 (n = 24)</td>
</tr>
<tr>
<td><strong>QoL (mean values) – 12 months</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGWB score (higher score better)</td>
<td>101.8 (n = 60) NR</td>
<td>102.3 (n = 57) NR</td>
<td>103.1 (n = 32) NR</td>
<td>103.2 (n = 25) NR</td>
</tr>
<tr>
<td>NHP score (lower score better)</td>
<td>1.6 (n = 46)</td>
<td>1.0 (n = 43)</td>
<td>0.9 (n = 22)</td>
<td>1.2 (n = 18)</td>
</tr>
<tr>
<td>Pain score (lower score better)</td>
<td>3.7 (n = 61)</td>
<td>2.3 (n = 58)</td>
<td>3.1 (n = 32)</td>
<td>2.4 (n = 25)</td>
</tr>
<tr>
<td>VAPS (lower score better)</td>
<td>15.7 (n = 60)</td>
<td>7.0 (n = 55)</td>
<td>15.1 (n = 31)</td>
<td>9.9 (n = 24)</td>
</tr>
<tr>
<td><strong>QoL (mean values) – 60 months</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGWB score (higher score better)</td>
<td>104.1 (n = 55) NR</td>
<td>101.6 (n = 56) NR</td>
<td>112.0 (n = 30) NR</td>
<td>102.5 (n = 25) NR</td>
</tr>
<tr>
<td>NHP score (lower score better)</td>
<td>1.3 (n = 47)</td>
<td>1.9 (n = 52)</td>
<td>0.7 (n = 27)</td>
<td>1.4 (n = 23)</td>
</tr>
<tr>
<td>Pain score (lower score better)</td>
<td>2.4 (n = 56)</td>
<td>2.0 (n = 56)</td>
<td>1.3 (n = 31)</td>
<td>2.6 (n = 24)</td>
</tr>
<tr>
<td>VAPS (lower score better)</td>
<td>11.5 (n = 56)</td>
<td>5.5 (n = 55)</td>
<td>6.2 (n = 31)</td>
<td>11.3 (n = 24)</td>
</tr>
</tbody>
</table>

ERCP, endoscopic retrograde cholangiopancreatography; NHP, Nottingham Health Profile part II, range 0–7 (lower score better); NR, not reported; Pain score, encompasses intensity and duration of pain in the last week, and frequency of pain and analgesic use in last 6 months, range 0–16 (lower score better); PGWB, Psychological General Well Being index, range 22–132 (higher score better); VAPS, Visual Analogue Pain Score, patients mark a non-graded 100-mm line ranging from no pain to unbearable pain to reflect intensity of pain during previous week (lower score better).

- a For the 14-year data, events that took place before surgery in the group randomised to cholecystectomy were not included, unless as a result of dropout from surgery.
- b n = 1 late complication after surgery.
- c Late complication after surgery.
- d Total 8 out of 137 randomised participants had died.
### FIGURE 6 Forest plot of participants having surgery (14 years).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Observation</th>
<th>Surgery</th>
<th>Risk ratio M–H, random (95% CI)</th>
<th>Risk ratio M–H, random (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Schmidt 2011</td>
<td>35</td>
<td>69</td>
<td>60</td>
<td>68</td>
</tr>
<tr>
<td>Schmidt 2011</td>
<td>11</td>
<td>33</td>
<td>27</td>
<td>31</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>102</td>
<td>87</td>
<td>99</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 0.05$, $\chi^2 = 2.11$, df = 1 ($p = 0.15$); $I^2 = 53$

Test for overall effect: $z = 3.52$ ($p = 0.0004$)

### FIGURE 7 Forest plot of pain attacks (14 years).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Observation</th>
<th>Surgery</th>
<th>Risk ratio M–H, random (95% CI)</th>
<th>Risk ratio M–H, random (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Schmidt 2011</td>
<td>23</td>
<td>69</td>
<td>8</td>
<td>68</td>
</tr>
<tr>
<td>Schmidt 2011</td>
<td>3</td>
<td>33</td>
<td>4</td>
<td>31</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>102</td>
<td>99</td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 0.64$, $\chi^2 = 2.93$, df = 1 ($p = 0.09$); $I^2 = 66$

Test for overall effect: $z = 0.71$ ($p = 0.48$)
Gallstone-related complications: total (14 years)
Significantly more participants randomised to observation (14/102; 14%) than those randomised to surgery (2/99; 2%) experienced any of the specified gallstone-related complications (risk ratio = 6.69; 95% CI 1.57 to 28.51; p = 0.01) (Figure 8).

Details of participants with acute cholecystitis, CBD stones and acute pancreatitis are presented below.

Gallstone-related complications: acute cholecystitis (14 years)
Participants randomised to observation were more likely to suffer from acute cholecystitis as a complication (Figure 9). Nine of the 102 (9%) participants randomised to observation and none of the 99 (0%) participants randomised to surgery experienced acute cholecystitis as a complication. The difference between intervention groups was statistically significant (risk ratio = 9.55; 95% CI 1.25 to 73.27; p = 0.03).

It is worth noting that, among those treated conservatively, new complicated events occurred more frequently in those in whom the initial diagnosis was acute cholecystitis than in those initially diagnosed as having uncomplicated symptomatic gallstones (biliary pain only).

Gallstone-related complications: common bile duct stones (14 years)
Few participants in both intervention groups suffered from CBD stones at the 14-year follow-up assessment (Figure 10). Four of the 102 (4%) participants randomised to observation and 1 of the 99 (1%) participants randomised to surgery experienced CBD stones. The difference between the groups was not statistically significant (risk ratio = 2.86; 95% CI 0.47 to 17.59; p = 0.26).

Gallstone-related complications: acute pancreatitis (14 years)
The risk of experiencing acute pancreatitis was the same in both intervention groups (Figure 11). One of the 102 (1%) participants randomised to observation and 1 of the 99 (1%) participants randomised to surgery experienced acute pancreatitis (risk ratio = 0.99; 95% CI 0.06 to 15.44; p = 0.99). Both events occurred in participants with uncomplicated symptomatic gallstones (biliary pain only) whereas participants with acute cholecystitis did not experience this complication.

Surgery-related complications: total (5 years)
As expected, the risk of surgery-related complications was significantly lower in the observation group (Figure 12). In total, 7 out of 102 (7%) participants randomised to observation and 19 out of 99 (19%) participants randomised to surgery experienced surgery-related complications (risk ratio = 0.36; 95% CI 0.16 to 0.81; p = 0.01).

Further details of individual surgery-related complications are presented below.

Surgery-related complications: intra-abdominal infection/bile leakage (5 years)
The risk of suffering from intra-abdominal infection/bile leakage was similar in both intervention groups (Figure 13). A total of 4 out of 102 (4%) participants randomised to observation and 3 out of 99 (3%) participants randomised to surgery experienced intra-abdominal infection or bile leakage (risk ratio = 1.30; 95% CI 0.30 to 5.63; p = 0.73). Five of the seven events were experienced by participants originally diagnosed with uncomplicated symptomatic gallstones (biliary pain only).

Surgery-related complications: wound infection/dehiscence (5 years)
The number of participants who suffered from wound infection/dehiscence after surgery was the same in both intervention groups (Figure 14). One of the 102 (1%) participants randomised to observation and 1 of the 99 (1%) participants randomised to surgery experienced wound infection or dehiscence (risk ratio = 0.99; 95% CI 0.06 to 15.44; p = 0.99). Both events occurred in participants diagnosed with uncomplicated symptomatic gallstones (biliary pain only) whereas no participants diagnosed with acute cholecystitis experienced this complication.
FIGURE 8  Forest plot of total gallstone-related complications (14 years).

FIGURE 9  Forest plot of episodes of acute cholecystitis (14 years).

FIGURE 10  Forest plot of episodes of CBD stones (14 years).
### FIGURE 11
Forest plot of episodes of acute pancreatitis (14 years).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Observation</th>
<th>Surgery</th>
<th>Risk ratio</th>
<th>Risk ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Schmidt 2011113</td>
<td>1</td>
<td>69</td>
<td>1</td>
<td>68</td>
</tr>
<tr>
<td>Schmidt 201146</td>
<td>0</td>
<td>33</td>
<td>0</td>
<td>31</td>
</tr>
<tr>
<td>Total (95% Cl)</td>
<td>102</td>
<td>99</td>
<td>100.0%</td>
<td>0.99 (0.06 to 15.44)</td>
</tr>
<tr>
<td>Total events</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $z = 0.01 (p = 0.99)$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### FIGURE 12
Forest plot of total surgery-related complications (5 years).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Observation</th>
<th>Surgery</th>
<th>Risk ratio</th>
<th>Risk ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Schmidt 2011113</td>
<td>5</td>
<td>69</td>
<td>10</td>
<td>68</td>
</tr>
<tr>
<td>Schmidt 201146</td>
<td>2</td>
<td>33</td>
<td>10</td>
<td>31</td>
</tr>
<tr>
<td>Total (95% Cl)</td>
<td>102</td>
<td>99</td>
<td>100.0%</td>
<td>0.36 (0.16 to 0.81)</td>
</tr>
<tr>
<td>Total events</td>
<td>7</td>
<td>19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: $\chi^2 = 0.91, df = 1 (p = 0.34); I^2 = 0%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $z = 2.46 (p = 0.01)$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study or subgroup</td>
<td>Observation Events</td>
<td>Total</td>
<td>Surgery Events</td>
<td>Total</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------</td>
<td>-------</td>
<td>----------------</td>
<td>-------</td>
</tr>
<tr>
<td>Schmidt 2011 113</td>
<td>3</td>
<td>69</td>
<td>2</td>
<td>68</td>
</tr>
<tr>
<td>Schmidt 2011 46</td>
<td>1</td>
<td>33</td>
<td>1</td>
<td>31</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>4</td>
<td>102</td>
<td>99</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: χ² = 0.07, df = 1 (p = 0.78); I² = 0%
Test for overall effect: z = 0.35 (p = 0.73)

FIGURE 13 Forest plot of intra-abdominal complications – infection/bile leakage (5 years).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Observation Events</th>
<th>Total</th>
<th>Surgery Events</th>
<th>Total</th>
<th>Weight</th>
<th>Risk ratio M-H, fixed (95% CI)</th>
<th>Risk ratio M-H, fixed (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmidt 2011 113</td>
<td>1</td>
<td>69</td>
<td>1</td>
<td>68</td>
<td>100.0%</td>
<td>0.99 (0.06 to 15.44)</td>
<td></td>
</tr>
<tr>
<td>Schmidt 2011 46</td>
<td>0</td>
<td>33</td>
<td>0</td>
<td>31</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>1</td>
<td>102</td>
<td>99</td>
<td></td>
<td>100.0%</td>
<td>0.99 (0.06 to 15.44)</td>
<td></td>
</tr>
</tbody>
</table>

Total events 1
Heterogeneity: not applicable
Test for overall effect: z = 0.01 (p = 0.99)

FIGURE 14 Forest plot of episodes of wound infection/dehiscence (5 years).
Surgery-related complications: bile duct injury
Figure 15 shows that only one participant randomised to surgery suffered from bile duct injury within 5 years (risk ratio = 0.31; 95% CI 0.01 to 7.42; p = 0.47).

Surgery-related complications: reoperation (5 years)
The number of participants who required reoperation was the same in both intervention groups (Figure 16). One of the 102 (1%) participants randomised to observation and 1 of the 99 (1%) participants randomised to surgery underwent reoperation (risk ratio = 0.99; 95% CI 0.06 to 15.44; p = 0.99). Both participants who underwent reoperation were originally diagnosed with uncomplicated gallstones (biliary pain only).

Surgery-related complications: minor complications (5 years)
Significantly fewer participants randomised to observation experienced minor complications (1/102; 1%) than participants randomised to surgery (13/99; 13%) (risk ratio = 0.11; 95% CI 0.02 to 0.56; p = 0.008) (Figure 17). A slightly larger proportion of participants originally diagnosed with acute cholecystitis experienced minor complications (8/64; 13%) than participants with uncomplicated symptomatic gallstones (biliary pain only) (6/137; 4%). The nature of minor complications was not described in the included trials.

Admission due to gallstone-related pain (5 years)
A total of 16 out of 102 (16%) participants randomised to observation and 5 out of 99 (5%) participants randomised to surgery were admitted to hospital because of gallstone-related pain (Figure 18). There was no statistically significant difference between the intervention groups at the 5-year follow-up (risk ratio = 2.69; 95% CI 0.57 to 12.68; p = 0.21).

For both uncomplicated symptomatic gallstones (biliary pain only) and acute cholecystitis groups, more participants randomised to observation than to surgery were subsequently admitted to hospital for gallstone-related pain (12 vs. 2 people with biliary pain and 4 vs. 3 people with acute cholecystitis). It is worth noting that the difference between intervention groups was statistically significant for participants with uncomplicated symptomatic gallstones (biliary pain only) ($\chi^2 = 7.79; p = 0.0052$) but not for those with acute cholecystitis ($\chi^2 = 0.10; p = 0.7542$).

Mortality rate (14 years)
Schmidt et al. reported that a total of 8 out of 137 participants with uncomplicated symptomatic gallstones (biliary pain only) had died by the 5-year follow-up, but they did not provide separate data for each intervention group. At the 14-year follow-up assessment, 8 out of 68 participants randomised to surgery and 11 out of 69 participants randomised to observation had died.

Schmidt et al. reported that 4 out of 31 participants with acute cholecystitis who were randomised to surgery had died by the 5-year follow-up, whereas no deaths were observed among participants randomised to observation. By the 14-year follow-up, 8 out of 31 participants randomised to surgery and 10 out of 33 participants randomised to observation had died. None of the deaths was caused by gallstone disease.

A total of 16 out of 102 (16%) participants randomised to observation and 21 out of 99 (21%) participants randomised to surgery died (Figure 19). The difference between the groups was not statistically significant (risk ratio = 0.73; 95% CI 0.41 to 1.31; p = 0.30).
<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Observation</th>
<th>Surgery</th>
<th>Risk ratio M–H, fixed (95% CI)</th>
<th>Risk ratio M–H, fixed (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Schmidt 2011113</td>
<td>0</td>
<td>69</td>
<td>0</td>
<td>68</td>
</tr>
<tr>
<td>Schmidt 2011146</td>
<td>0</td>
<td>33</td>
<td>1</td>
<td>31</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>102</td>
<td>99</td>
<td>100.0%</td>
<td>0.31 (0.01 to 7.42)</td>
</tr>
<tr>
<td>Total events</td>
<td>1</td>
<td>1</td>
<td>100.0%</td>
<td>0.31 (0.01 to 7.42)</td>
</tr>
</tbody>
</table>

**FIGURE 15** Forest plot of bile duct injury cases (5 years).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Observation</th>
<th>Surgery</th>
<th>Risk ratio M–H, fixed (95% CI)</th>
<th>Risk ratio M–H, fixed (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Schmidt 2011113</td>
<td>1</td>
<td>69</td>
<td>1</td>
<td>68</td>
</tr>
<tr>
<td>Schmidt 2011146</td>
<td>0</td>
<td>33</td>
<td>0</td>
<td>31</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>102</td>
<td>99</td>
<td>100.0%</td>
<td>0.99 (0.06 to 15.44)</td>
</tr>
<tr>
<td>Total events</td>
<td>1</td>
<td>1</td>
<td>100.0%</td>
<td>0.99 (0.06 to 15.44)</td>
</tr>
</tbody>
</table>

**FIGURE 16** Forest plot of reoperation cases (5 years).

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Observation</th>
<th>Surgery</th>
<th>Risk ratio M–H, fixed (95% CI)</th>
<th>Risk ratio M–H, fixed (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Schmidt 2011113</td>
<td>0</td>
<td>69</td>
<td>6</td>
<td>68</td>
</tr>
<tr>
<td>Schmidt 2011146</td>
<td>1</td>
<td>33</td>
<td>7</td>
<td>31</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>102</td>
<td>99</td>
<td>52.4%</td>
<td>0.11 (0.02 to 0.56)</td>
</tr>
<tr>
<td>Total events</td>
<td>13</td>
<td>13</td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>

**FIGURE 17** Forest plot of minor complications (5 years).
### Study or subgroup | Observation | Surgery | Risk ratio (M–H, fixed (95% CI)) |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmidt 2011\textsuperscript{113}</td>
<td>12</td>
<td>69</td>
<td>\textsuperscript{5.91 (1.37 to 25.44)}</td>
</tr>
<tr>
<td>Schmidt 2011\textsuperscript{46}</td>
<td>4</td>
<td>33</td>
<td>\textsuperscript{1.25 (0.30 to 5.15)}</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>102</td>
<td>99</td>
<td>\textsuperscript{2.69 (0.57 to 12.68)}</td>
</tr>
<tr>
<td>Total events</td>
<td>16</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2 = 0.01$, df = 1 ($p = 0.94$); $I^2 = 0$

Test for overall effect: $z = 1.05$ ($p = 0.30$)

FIGURE 18 Forest plot of number of admissions due to gallstone-related pain (5 years).

### Study or subgroup | Observation | Surgery | Risk ratio (M–H, fixed (95% CI)) |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmidt 2011\textsuperscript{113}</td>
<td>8</td>
<td>69</td>
<td>\textsuperscript{0.72 (0.31 to 1.67)}</td>
</tr>
<tr>
<td>Schmidt 2011\textsuperscript{46}</td>
<td>8</td>
<td>33</td>
<td>\textsuperscript{0.75 (0.34 to 1.66)}</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>102</td>
<td>99</td>
<td>\textsuperscript{2.69 (0.57 to 12.68)}</td>
</tr>
<tr>
<td>Total events</td>
<td>16</td>
<td>21</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2 = 2.33$, df = 1 ($p = 0.13$); $I^2 = 57$

Test for overall effect: $z = 1.25$ ($p = 0.21$)

FIGURE 19 Forest plot of number of deaths (14 years).
Relevant outcomes according to the treatment received by participants

In both trials, a certain number of participants did not receive the treatment to which they were randomised but swapped over to receive the other intervention: a proportion of participants randomised to observation (46 people) underwent cholecystectomy and a proportion of participants randomised to receive surgery (12 people) opted for conservative management. The flow chart in Figure 20 illustrates the main outcomes according to the treatment that participants, in both trials, received. Figures 21 and 22 present this information for each trial (Schmidt et al.113 and Schmidt et al.46) separately. Note that in Figures 20 and 21 the numbers quoted for admission to hospital for gallstone-related pain for the observation group differ from those in Table 5 as a result of a discrepancy in table III of the Vetrhus et al. paper. Moreover, the discrepancy between the 5 and 14 years’ findings is because outcomes at 5 years included events which occurred after randomisation but before surgery, whereas outcomes at 14 years did not include events that took place before surgery.

![Flow chart illustrating outcomes according to treatment received](image)

**FIGURE 20** Outcomes according to treatment received (both trials combined). AP, acute pancreatitis; GS, gallstone.
FIGURE 21 Outcomes for the treatment received by participants with uncomplicated symptomatic gallstone disease only (Schmidt et al. 2011). AP, acute pancreatitis; GS, gallstone.

FIGURE 22 Outcomes according to the treatment received by participants with acute cholecystitis only (Schmidt et al. 2011). AP, acute pancreatitis; GS, gallstone.
Outcomes not included in meta-analyses

Further surgical intervention required
Schmidt et al.\textsuperscript{113} reported that, at the 14-year follow-up, 4 out of 60 (7\%) participants with uncomplicated symptomatic gallstones (biliary pain only) randomised to surgery who did undergo cholecystectomy subsequently required endoscopic retrograde cholangiopancreatography. Common bile duct stones were detected in one of these four participants.

Median time to surgery (from randomisation)
Schmidt et al.\textsuperscript{113} reported that the median time to surgery for participants with uncomplicated symptomatic gallstones (biliary pain only) was 3 months (range 0–68 months) for participants randomised to surgery and 28 months for participants randomised to observation (no range was given for the observation group). Schmidt et al.\textsuperscript{46} stated that patients who were randomised to surgery, on average, underwent an operation 4 months (median) after randomisation (range 1–13 months). No details were provided for those patients randomised to observation who eventually underwent surgery.

Quality of life
We were not able to include QoL measures in the statistical analyses as measures of variability were not reported and were not available from the trial investigators. Quality-of-life measures were assessed only at 5 years. In the paragraphs below, scores for the observation group are reported first, followed by scores for the surgery group. None of the differences between groups was statistically significant.

Quality of life: Psychological General Well Being Index
In the Schmidt et al.\textsuperscript{113} trial both intervention groups reported PGWB scores lower than 105 at 6 months, which is the score normally expected in healthy control subjects (mean score of 99.9 for the observation group and 103.3 for the surgery group, respectively).\textsuperscript{113} This indicates a slightly poorer level of general well-being than in healthy control subjects. In addition, the observation group reported lower scores than the surgery group. This difference was, however, not statistically significant. Notably, at this time point, 7 of the 35 participants in the observation group who crossed over to surgery had actually been operated on.

At 6 months, 46 participants with acute cholecystitis reported higher scores and, therefore, greater well-being than the average score of 105 expected in healthy control subjects (mean score of 110.2 for the observation group and 106.2 for the surgery group). In contrast to the Schmidt et al.\textsuperscript{113} trial, participants in the observation group reported higher (but not significantly higher) scores than participants who underwent surgery.

At 12 months, participants in both trials reported levels of well-being lower than those expected of healthy control subjects. In the Schmidt et al.\textsuperscript{113} trial the mean PGWB scores were 101.8 for the observation group and 102.3 for the surgery group. Similarly, in the Schmidt et al.\textsuperscript{46} trial the mean PGWB scores were 103.1 for the observation group and 103.2 for the surgery group. It is worth noting, however, that, at this time point, participants’ scores in both trials were similar.

In both trials, participants managed conservatively reported higher well-being scores at 60 months than those who underwent surgery. In the Schmidt et al.\textsuperscript{113} trial the mean PGWB score was 104.1 for the observation group compared with 101.6 for the surgery group, whereas in the Schmidt et al.\textsuperscript{46} trial the mean PGWB score was 112.0 for the observation group and 102.5 for the surgery group. In Schmidt et al. participants randomised to observation reported levels of general well-being greater than scores which would be expected in healthy control subjects.\textsuperscript{115}

Quality of life: Nottingham Health Profile part II
At all time points, both trials reported NHP scores of < 2, indicating a limited number of specified domains (i.e. job, housework, social life, home life, sex life, interests/hobbies, holidays) affected by gallstone disease. In particular, the mean NPH scores for the observation group and the surgery group were, respectively,
1.6 and 1.1,113 and 1.1 and 1.246 at 6 months; 1.6 and 1.0113 and 0.9 and 1.246 at 12 months; and 1.3 and 1.9113 and 0.7 and 1.446 at 60 months. In both trials, scores did not vary significantly over time or between intervention groups.

**Quality of life: pain score**

Pain scores among participants with uncomplicated symptomatic gallstones (biliary pain only)113 showed a tendency to decrease between 6 and 60 months, with all scores being at the lower end of the possible range of 0–16. At 6 months, participants in the observation group had a mean score of 4.1 and participants in the surgery group a mean score of 2.2. At 12 months, the mean score was 3.7 and 2.3 for the observation group and the surgery group, respectively, whereas at 60 months the scores were 2.4 and 2.0, respectively. Pain scores were consistently higher for the observation group than for the surgery group (albeit the difference was not statistically significant).

Mean scores among participants with acute cholecystitis46 were also generally at the low end of the range (2.1 and 2.0 at 6 months, 3.1 and 2.4 at 12 months and 1.3 and 2.6 at 60 months for the observation group and surgery group, respectively). Scores for the surgery group increased between 6 and 60 months while scores for the observation group increased from 6–12 months and then decreased between 12 and 60 months. Furthermore, at 60 months, pain score for the surgery group was greater than that of the observation group (the only time point at which this occurred in either of the two trials).

**Quality of life: Visual Analogue Pain Score**

Schmidt et al.113 reported mean VAPS at the lower end of the possible range (0–100) among participants with biliary pain only (14.7 and 9.4 at 6 months, 15.7 and 7.0 at 12 months and 11.5 and 5.5 at 60 months for the observation group and surgery group, respectively). In particular, scores in the observation group were consistently higher (but not significantly higher) than those in the surgery group. Pain scores tended to decrease in the surgery group between 6 and 60 months, whereas in the observation group scores increased between 6 and 12 months and subsequently decreased to pre-12-month levels at 60 months.

Mean VAPS in participants with acute cholecystitis allocated to surgery46 increased over time while in participants managed conservatively it varied over time, with a similar trend to that observed in the Schmidt et al. trial (8.1 and 5.4 at 6 months, 15.1 and 9.9 at 12 months and 6.2 and 11.3 at 60 months for the observation group and surgery group, respectively).113

**Summary**

This assessment was based on the clinical data derived from two RCTs (published in six reports) with a total of 201 participants. Both trials were judged to be at low risk of bias. Table 6 presents a summary of the outcomes which were included in the meta-analyses. A summary of the clinical effect size for outcomes assessed at 5 years and for those assessed at 14 years is presented in Figures 23 and 24, respectively.

Participants randomised to surgery were significantly more likely to undergo surgery and had a greater risk of experiencing surgery-related complications as well as minor complications. Participants randomised to observation were at significantly greater risk of experiencing gallstone-related complications, in particular acute cholecystitis. Within participants with initial diagnosis of uncomplicated symptomatic gallstone (biliary pain only), those randomised to observation were more likely to experience pain attacks and be admitted to hospital for gallstone-related pain than those randomised to surgery. Mortality risk was greater (but not significantly greater) among participants randomised to surgery.
### TABLE 6 Summary of meta-analysis results (n = 201 in two trials)

<table>
<thead>
<tr>
<th>Event</th>
<th>Risk ratio (95% CI)</th>
<th>Test for overall effect (p-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Undergoing surgery (14 years)</td>
<td>0.50 (0.34 to 0.73)</td>
<td>0.0004</td>
</tr>
<tr>
<td>Pain attacks (14 years)</td>
<td>1.62 (0.43 to 6.17)</td>
<td>0.48</td>
</tr>
<tr>
<td>Mortality (14 years)</td>
<td>0.73 (0.41 to 1.31)</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>Gallstone-related complications (all 14 years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>6.69 (1.57 to 28.51)</td>
<td>0.01</td>
</tr>
<tr>
<td>Acute cholecystitis</td>
<td>9.55 (1.25 to 73.27)</td>
<td>0.03</td>
</tr>
<tr>
<td>CBD stones</td>
<td>2.86 (0.47 to 17.59)</td>
<td>0.26</td>
</tr>
<tr>
<td>Acute pancreatitis</td>
<td>0.99 (0.06 to 15.44)</td>
<td>0.99</td>
</tr>
<tr>
<td><strong>Surgery-related complications (all 5 years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>0.43 (0.21 to 0.91)</td>
<td>0.03</td>
</tr>
<tr>
<td>Intra-abdominal infection/bile leakage</td>
<td>1.30 (0.30 to 5.63)</td>
<td>0.73</td>
</tr>
<tr>
<td>Wound infection/dehiscence</td>
<td>0.99 (0.06 to 15.44)</td>
<td>0.99</td>
</tr>
<tr>
<td>Bile duct injury</td>
<td>0.31 (0.01 to 7.42)</td>
<td>0.47</td>
</tr>
<tr>
<td>Reoperation</td>
<td>0.99 (0.06 to 15.44)</td>
<td>0.99</td>
</tr>
<tr>
<td>Minor complications</td>
<td>0.11 (0.02 to 0.56)</td>
<td>0.008</td>
</tr>
<tr>
<td>Admission due to gallstone-related pain (5 years)</td>
<td>2.69 (0.57 to 12.68)</td>
<td>0.21</td>
</tr>
</tbody>
</table>

**Note**

A risk ratio of < 1 favours observation.
Number of participants undergoing surgery

Pain attacks

Gallstone-related complications
- Acute cholecystitis
- CBD stones
- Acute pancreatitis

Surger-related complications
- Intra-abdominal infection/bile leakage
- Wound infection/dehiscence
- Bile duct injury
- Reoperation
- Minor complications

Admission due to gallstone-related pain

Mortality rate

Risk ratio (95% CI)

Number of participants undergoing surgery 0.47 (0.29 to 0.77)

Pain attacks Not reported

Gallstone-related complications 3.80 (1.36 to 10.58)
- Acute cholecystitis 6.65 (1.25 to 35.41)
- CBD stones 4.14 (0.73 to 23.65)
- Acute pancreatitis 0.32 (0.03 to 3.03)

Surger-related complications 0.43 (0.21 to 0.91)
- Intra-abdominal infection/bile leakage 1.30 (0.30 to 5.63)
- Wound infection/dehiscence 0.99 (0.06 to 15.44)
- Bile duct injury 0.31 (0.01 to 7.42)
- Reoperation 0.99 (0.06 to 15.44)
- Minor complications 0.11 (0.02 to 0.56)

Admission due to gallstone-related pain 2.69 (0.57 to 12.68)

Mortality rate Not reported

Risk ratio (95% CI)

Number of participants undergoing surgery 0.50 (0.34 to 0.73)

Pain attacks 1.62 (0.43 to 6.17)

Gallstone-related complications 6.69 (1.57 to 28.51)
- Acute cholecystitis 9.55 (1.25 to 73.27)
- CBD stones 2.86 (0.47 to 17.59)
- Acute pancreatitis 0.99 (0.06 to 15.44)

Surger-related complications Not reported
- Intra-abdominal infection/bile leakage Not reported
- Wound infection/dehiscence Not reported
- Bile duct injury Not reported
- Reoperation Not reported
- Minor complications Not reported

Admission due to gallstone-related pain Not reported

Mortality rate 0.73 (0.41 to 1.31)

FIGURE 23 Summary of meta-analyses results (5-year data) [risk ratio (95% CI)].

FIGURE 24 Summary of meta-analyses results (14-year data) [risk ratio (95% CI)].
Chapter 5  Assessment of cost-effectiveness

Systematic review of existing cost-effectiveness evidence

A formal systematic review of economic evaluations studies was not attempted as initial scoping literature searches indicated that there were no existing economic evaluations comparing conservative management with surgery from the perspective of the UK NHS. Only two cost–utility papers based on the UK setting were identified, but they compared early with delayed laparoscopic cholecystectomy. Therefore, this chapter focuses on presenting the methods and the results of a de novo economic model.

Economic modelling

Model development

A de novo economic model was developed to compare alternative treatment strategies for people with symptomatic gallstone disease (biliary pain or cholecystitis). According to the purpose of this assessment two strategies were considered:

- conservative management
- surgical management (cholecystectomy).

The structure of the model was informed by the findings of the trials included in the systematic review of clinical effectiveness, other existing evidence, as well as by the advice from health-care professionals within the research team for this assessment. The perspective adopted for the analysis is that of the UK NHS and the Personal Social Services.

The assumed care pathway of the model

The model described in this chapter is based on two clinically relevant care pathways for gallstone disease: a surgery care pathway and a conservative management care pathway (Figures 25 and 26). Both pathways were derived from the care pathway reported in Chapter 2 (Definition of the decision problem). As the current standard treatment for gallstone disease in the UK is cholecystectomy, the conservative management pathway portrays a plausible pathway that people with gallstones can follow.

The first care pathway (Figure 25) considers patients who are treated with surgery (mainly laparoscopic cholecystectomy). There are five health states that could arise from the surgical management: peri- and post-operative complications, no symptoms, post-surgical symptoms (such as pain that persists after surgery) and death. Patients who survive surgery can either have no complications or suffer from peri- or post-operative complications. These complications can either be managed without any further surgical intervention or require further surgery (e.g. surgery for bile duct injury). Those patients who experience no complications could end up with symptoms or they could have no symptoms. In subsequent cycles there is always a chance that patients die when they are in either a symptom or no symptom state from all-cause age-related mortality.

The second pathway (Figure 26) considers three health states for patients with gallstone disease who are managed conservatively: no symptoms, symptoms or death. Patients who are free from symptoms after conservative treatment have a chance of staying in this state (no symptoms) or they may continue to experience the recurrence of symptoms over time and, therefore, move into a symptoms state. Patients who continue to experience symptoms have a chance of continuing to be treated conservatively or they can be offered surgery. As in the surgery pathway, patients always have a chance of dying from all-cause age-related mortality. The key outcome of the conservative management (number of patients without...
In subsequent cycles there is always a chance that patients die when they are in either symptoms or no-symptoms state from age-related all-cause mortality.

**FIGURE 25** Surgery care pathway. Rectangles represent treatment options; ovals represent health states; arched arrows above the ovals represent health states in which people may return; and arrows indicate the possible directions in which individuals could move at the end of each cycle.

**FIGURE 26** Conservative management care pathway. Rectangles represent treatment options; ovals represent health states; arched arrows above the ovals represent health states in which people may return; and arrows indicate the possible directions in which individuals could move at the end of each cycle.
symptoms) will be influenced by whether or not the treatment resolves the symptoms and, therefore, whether or not patients seek any further medical intervention, in particular surgery.

**Model structure**

A Markov model was developed to model the alternative management strategies (i.e. conservative management or surgery) that patients with symptomatic gallstone disease may be offered over time and to provide estimates of costs, clinical effectiveness [measured in quality-adjusted life-years (QALYs)] and cost-effectiveness (Figure 27). The model estimates the costs and consequences of both interventions and of any further events – such as the treatment for recurrent symptoms and/or complications. The model was developed using TreeAge Pro 2012 (TreeAge Software, Inc., Williamstown, MA, USA).

![Figure 27 Markov model structure.](image-url)
The model was based on a hypothetical cohort of patients presenting with symptomatic gallstone disease (biliary pain or cholecystitis). In the model, symptomatic patients receive an initial treatment of either conservative management or surgery (cholecystectomy) and then move into different health states, either surviving or dying. The assumption that over a given period of time a patient could die is always built into the model. Death takes into account that patients suffering from gallstone disease (i) are exposed to a very small risk of death when they undergo surgery and (ii) have a chance of dying from all other causes at any point in time (this chance is assumed to be equivalent to that of all-cause age-related mortality).\textsuperscript{118} Death is referred to as an absorbing state (an absorbing state in a Markov model is a state that once entered cannot be exited again). Those patients who survive cholecystectomy end up in one of two health states: they can either have peri- or post-operative complications or they can have no complications for the remainder of the cycle. Those patients who have post-operative complications (e.g. bile duct injury, port incisional hernia) remain in the complications post-surgery state for the remainder of the cycle.

Similarly, those patients who have conservative management end up in one of two health states: their symptoms can either be resolved or they can persist continuously or intermittently over time. It is assumed that no further treatment is sought by those whose symptoms resolve. Those individuals who continue to experience symptoms can either undergo surgery or they can continue to be treated conservatively. In the model it is assumed that all individuals who continue to experience symptoms will present for surgery within 5 years, so by the end of 5 years all the people left under conservative management are symptom free.

The following are the key assumptions of the economic modelling exercise:

- The time horizon of the model is 5 years. This time horizon was chosen as long-term follow-up data\textsuperscript{46} indicate that the majority of people with symptomatic gallstones undergo cholecystectomy during the first 5 years.
- The cycle length (i.e. the time period by which transitions between health states are modelled) is 1 year.
- In the base case, the typical person with symptomatic gallstone disease entering the model is a female of 51 years of age. This choice is justified by the average age at which people currently undergo surgery to remove their gallbladder and by the fact that women are more likely to suffer from gallstone disease than men.\textsuperscript{84}

The results of the model are presented in terms of incremental cost per QALY. The costs and benefits incurred beyond 1 year were discounted at 3.5% per year in accordance with the current National Institute for Health and Care Excellence (NICE) guidelines.\textsuperscript{119}

\textit{Data requirements and model inputs}

\textbf{Estimations of model probabilities}

The model uses probabilities:

- complications after surgery
- resolution of complications
- resolution of symptoms following surgery (symptomatic people can be cured from their symptoms – cholecystitis/biliary pain following surgery)
- continuing to experience symptoms following initial conservative management;
- transitioning to surgery following conservative management (assumed to be concentrated in those who continue to experience symptoms
- surgical and all-cause mortality.
Estimates of probabilities of the events were derived from the results of the systematic review of clinical effectiveness reported in Chapter 6 as well as other UK sources. For probabilistic sensitivity analyses, appropriate probability distributions were assigned.

**Complications during and after laparoscopic surgery**

According to the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) the current rate of major bile duct injury in laparoscopic cholecystectomy has stabilised at 0.1–0.6% and series with no major bile duct injuries have been reported. Although many believe that the rate of major bile duct injury in open cholecystectomy is lower than laparoscopic cholecystectomy, controversy remains. Post-operative complications include bile leak, retained stone, wound infection, pneumonia and bile duct injury. The estimate used in the model for the probability of having peri-operative complications was 0.1 (10%), inclusive of those patients who had their laparoscopic cholecystectomy converted into open cholecystectomy. This value was based on advice from clinical experts and is a conservative assumption (in the sense that it is likely to be a lower rate and, based on SAGES data; therefore, our estimates of cost-effectiveness of surgery are less favourable than they would have been if SAGES data had been used).

An estimate for the proportion of patients whose complications require further surgery was based on the information available to patients who undergo cholecystectomy in the NHS in England and expert opinion. These values vary from 0.01 to 0.002 (1/100 to 1/500) and the estimate used in the base analysis was 0.01 (1/100).

**Symptoms after surgery**

Although cholecystectomy is the preferred treatment for symptomatic gallstones, the relationship between cholecystectomy and post-cholecystectomy symptoms is still unclear. Individuals with gallstones have various abdominal symptoms that may be caused by gallstones or may be present as a separate condition but with common physiology. The accompanying abdominal symptoms are referred to as functional gastrointestinal disorders. As both functional disorders and gallstones manifest with the same clinical symptoms (pain and discomfort) it is difficult to distinguish between the two conditions. Lack of clear distinction makes it difficult to treat the symptoms if they remain after the operation. Existing literature suggests that a proportion of people may still suffer from persistent or de novo symptoms after surgery. Post-cholecystectomy syndrome occurs when abdominal symptoms persist after cholecystectomy. Reports suggest that about 4–40% of individuals who have their gallbladder removed may continue to experience symptoms after surgery. The probability of having symptoms after laparoscopic cholecystectomy was informed by existing evidence and advice from clinical experts. The value used in the base-case analysis was 0.1 (10%).

**Symptoms and surgery after conservative management**

For people with gallstones treated conservatively, the model utilises the probability of individuals developing symptoms following initial treatment. The probability of experiencing recurrent symptoms while treated conservatively is based on the findings of the two RCTs reported in the systematic review of clinical effectiveness (Chapter 4). The estimate was derived from the number of patients in conservative management who switched to surgery or required further medical treatment during the 5-year follow-up period. Forty-five out of 102 symptomatic people received further treatment, mainly surgery, over a 5-year period after randomisation to conservative management. The 5-year probability of presenting for surgery was converted into a fixed instantaneous rate and was reconvered into an annual probability using the following formula:

$$ R = -\frac{\ln(1-p)}{t} $$

(1)

where $p$ is the probability, $R$ is the rate, $t$ is the time period of interest and ln is natural log.

The rate based on above data is therefore:

$$ -\frac{\ln(1-0.44)}{5} = 0.115964 $$

(2)
The 1-year probability of having symptoms is therefore:

\[
1\text{-year probability} = 1 - \exp(-0.115964 \times 1) = 0.109493
\]

The model was specified so that the proportion of patients remaining symptom free under conservative management increased over time (as those continuing to experience symptoms presented for surgery). As such, it was assumed that all those individuals remaining in conservative management at 5 years were symptom free.

**Risk of death attached to surgery**

This information was based on estimates of risk modelling for the probability of death after cholecystectomy using simulations for people that received elective surgery. The estimate used in the base-case model was 0.00073 (Table 7).

**All-cause mortality rates in the UK**

The probability that people with gallstone disease entering the model may die is based on the annual rates of all-cause age-specific mortality for both men and women (Table 8).

| TABLE 7 Summary of probability parameters used in model |
|---------------------------------------------|---|---|---|
| Definition | Value | Distribution | Source/notes |
| Probability surgical mortality | 0.00073 | Applied deterministically | Harrison 2012
| Probability surgical complications | 0.10 | Applied deterministically | Clinical expert advice |
| Probability symptom free post-conservative management | 0.56 | Beta | Systematic review |
| Probability of getting surgery post-conservative management | 0.44 | Beta | 5-year probability reported in the systematic review converted to a 1-year probability within the model |
| Probability surgical complication needs further treatment | 0.01 | Applied deterministically | Literature and clinical advice |
| Probability of having symptoms after surgery | 0.10 | Applied deterministically | Clinical expert advice |

| TABLE 8 All-cause age-specific mortality rates |
|---------------------------------|---|---|
| Cycle | Men | Women |
| 0 | 0.003874 | 0.002496 |
| 1 | 0.004228 | 0.002831 |
| 2 | 0.004626 | 0.003019 |
| 3 | 0.005019 | 0.003503 |
| 4 | 0.005705 | 0.003615 |
**Resource utilisation and cost estimation**

Costs are presented in pounds sterling (£) in 2011-12 prices. Details of the sources used are summarised in Table 9. Data included the direct health service costs associated with each treatment strategy. The following resource use data were required to estimate costs incurred by the NHS: staff time, consumables, overheads and all the resources associated with any subsequent patient follow-up and management. Surgical procedures were mapped to their appropriate health-care resource group (HRG) and costed using *NHS Reference Costs* or the payment by results national tariff. The unit cost data for other resource utilisation was extracted from the literature or obtained from other relevant sources [e.g. Personal Social Service Research Unit].

The cost of the surgery was based on the cost of laparoscopic cholecystectomy with the length of stay of 1 day without complications. Laparoscopic cholecystectomy was chosen as it is the most frequently performed surgical procedure for people presenting with cholecystitis or biliary pain. There are two main dimensions of outcome after laparoscopic cholecystectomy: surgical complications or no complications. The cost of peri-operative complications was assumed to be the same for both surgical procedures, open and laparoscopic. Additional costs were considered for those people whose complications required further surgical interventions such as the treatment of bile duct injury. These additional costs were based on the average cost of all services relating to hepatobiliary procedures with and without complications. It was also assumed that these people had four follow-up visits to the hepatobiliary clinic every year. Costs were also included for people who experienced pain after cholecystectomy (post-cholecystectomy syndrome). People who had no surgical complications could either be completely cured or alternatively could have suffered from persistent symptoms (post-cholecystectomy syndrome). Based on clinical advice the cost of unresolved symptoms was assumed to involve one general practitioner and one outpatient visit per year.

**TABLE 9** Summary of unit costs used in the analysis

<table>
<thead>
<tr>
<th>Resource</th>
<th>Value</th>
<th>Distribution</th>
<th>Source/notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholecystectomy surgery</td>
<td>£2343</td>
<td>Gamma</td>
<td>Elective inpatient HRG data, GA10D laparoscopic cholecystectomy, 19 years and over, with length of stay 1 day or more, without CCs84</td>
</tr>
<tr>
<td>Initial conservative management</td>
<td>£179</td>
<td>Gamma</td>
<td>Consultant led: first attendance non-admitted face to face84</td>
</tr>
<tr>
<td>Follow-up conservative management</td>
<td>£191</td>
<td>Gamma</td>
<td>Based on one hospital outpatient visit (consultant led: follow-up attendance non-admitted face to face) and one GP visit £155 + £3684,135</td>
</tr>
<tr>
<td>Operative surgical complications</td>
<td>£2877</td>
<td>Gamma</td>
<td>Elective inpatient HRG data, GA10F open or laparoscopic cholecystectomy with CCs84</td>
</tr>
<tr>
<td>Post-operative corrective surgery</td>
<td>£6123</td>
<td>Gamma</td>
<td>GA03A&amp;B to GA013 A&amp;B average of hepatobiliary procedures categories 1–7 with and without CCs84</td>
</tr>
<tr>
<td>Post-cholecystectomy syndrome</td>
<td>£191</td>
<td>Gamma</td>
<td>Based on one hospital outpatient visit (consultant led: follow-up attendance non-admitted face to face) and one GP visit £155 + £3684,135</td>
</tr>
<tr>
<td>Surgical complications follow-up</td>
<td>£532</td>
<td>Gamma</td>
<td>Four follow-up outpatient consultant-led visits: follow-up attendance non-admitted face to face84</td>
</tr>
<tr>
<td>Inpatient stayb</td>
<td>£949</td>
<td>Gamma</td>
<td>Non-elective inpatient (short stay) HRG data. Average of all endoscopic or percutaneous, hepatobiliary or pancreatic procedures, with and without complications84</td>
</tr>
<tr>
<td>GP visit</td>
<td>£36</td>
<td>Gamma</td>
<td>Per surgery consultation lasting 11.7 minutes135</td>
</tr>
</tbody>
</table>

CC, complication; GP, general practitioner.

a GA10D, GA10F, GA03A&B and GA013A&B correspond to the specific codes allocated to the different hepatobiliary-related treatments.

b Value of cost of non-elective inpatient stay for all types symptomatic people in the conservative management strategy used in sensitivity analysis.
The resources needed to provide conservative management included the number of visits to different health care providers, in particular the general practitioner (GP) and hospital outpatient department. In the base-case analysis it was assumed that all people presenting with biliary pain or cholecystitis had one hepatobiliary consultant clinic visit after the initial presentation (all people in the total cohort had one initial presentation at clinic). People whose symptoms were not resolved and continued with conservative management were assumed to have two additional visits within the first year of presentation to secondary care (one to the GP and a follow-up visit to the hepatobiliary clinic) and two similar visits each year in the following cycles. The remainder of people whose symptoms were not resolved were assumed to have had laparoscopic surgery and followed the surgery care pathway. Pain relief medications were not considered in the base-case analysis as these costs are either incurred by the people themselves (rest of the UK) or are free (Scotland).

**Estimation of total cost of strategies**

The total costs of the treatment strategies were determined by using recursive cost in the Markov model. As the model tree expands from the left to the right, the ‘cost’ variable is modified by adding new cost variables. In this way the value of ‘cost’ at each terminal node is unique to the path from the root node to that terminal node. Discounted costs are considered in the model to estimate the cost of each strategy by using the following formula:

\[
\text{Cost}_{\text{strategy}} = \sum \text{cost}_{\text{cycle}} / (1 + \text{discount \ rate})^{\text{cycle}}
\]

**Quality-of-life measures**

Quality-of-life weights associated with the different outcomes of treatment and follow-up of people with symptomatic gallstones were identified in order to extend the economic evaluation into a cost–utility analysis. A focused search of the Cost-effectiveness Analysis Registry (Appendix 1) was performed to identify QoL data relevant to a UK setting. The search indicated that there were 15 studies reporting utility weights. None of these studies compared conservative management with cholecystectomy. There were six papers that compared outcomes of different interventions such as mini laparotomy, lithotripsy, open cholecystectomy with laparoscopic cholecystectomy\(^{116,117,136-139}\) and one paper compared the different methods of valuing health-related QoL techniques, i.e. visual analogue scale and the standard gamble in measuring people preferences for outcomes of gallstone disease.\(^{140}\)

Two of the studies\(^{117,139}\) that were conducted alongside RCTs used the European Quality of Life-5 Dimensions (EQ-5D). Although Nilsson and colleagues\(^{139}\) collected data at five different time points (pre-operatively, post-operatively, 1 week, 1 month and 1 year), they did not report preference-based weights or estimate a QALY. Macafee \textit{et al.}\(^{117}\) compared early with delayed cholecystectomy and reported utility scores of 0.85 (standard deviation 0.26) for the early group and 0.93 (standard deviation 0.13) for the conventional (delayed) group (QALYs estimated using the EQ-5D questionnaire were calculated 30–35 days after laparoscopic surgery). The final study\(^{138}\) estimated QALYs for different health states relating to two treatment options using a time trade-off method. The utility score for laparoscopic cholecystectomy was found to be similar to those of the Macafee \textit{et al.}\(^{117}\) study, 0.90 (95% CI 0.87 to 0.93). In the model, utility values were assigned to the types of potential different morbidities that could be associated with the procedures or health state represented in the model. \textit{Table 10} provides a summary of the estimates used in the model. Estimates of the utility for people who had cholecystectomy were based on the results of a RCT.\(^{117}\) The utility estimate for people whose symptoms were resolved using laparoscopic cholecystectomy or conservative management was 0.93. The rest of the estimates were based on a study that used standard gamble to quantify how much a given type of morbidity would detract from their QoL.\(^{140}\) The estimation of QALY values took into account the time people stayed in the state. For example, individuals who had further surgery were in a reduced state of health and were assigned a utility value of 0.64 for a month and 0.80 for the rest of the year. By applying utility weights to the modelled states and temporary events within states in the Markov model, QALYs gained over the 5-year follow-up period were tracked.
Assessment of cost-effectiveness

The base-case analysis was based on the costs and outcomes of a cohort of 51-year-old symptomatic women (the mean age of people receiving cholecystectomy in England and Wales). The outcome is the incremental cost per QALY. Data on the outcome are presented in two ways. First, the mean costs, QALYs and the incremental cost-effectiveness ratio (ICER), where appropriate, are calculated. These are ratios of the differences in costs and interventions divided by the differences in clinical effectiveness between the different strategies. These data reflect the rate of return in QALYs to the quantity of resources used (measured in monetary values). The second way in which the cost-effectiveness of the alternative care pathways is presented is in terms of cost-effectiveness acceptability curves (CEACs). CEACs which are derived from probabilistic sensitivity analysis are used to illustrate the uncertainty caused by the statistical variability in the parameters used in the model. CEACs illustrate the likelihood that a strategy is cost-effective at various threshold values for society’s willingness to pay for an additional QALY. The value society is willing to pay for a QALY is unclear, but in the UK NICE tends to recommend that an intervention is cost-effective when the incremental cost per QALY is less than £20,000–30,000.\textsuperscript{119}

Probabilistic and deterministic sensitivity analyses

Probabilistic and deterministic sensitivity analyses were applied to the model in order to assess the robustness of the results to realistic variations in the model parameters. The point estimates applied to costs, outcomes and probabilities of events in the model are all estimates of true population values. As such, distributions are assigned to these parameters to characterise the surrounding uncertainty due to sampling variation. Monte Carlo simulation was used to repeatedly sample from the distributions assigned to the parameters (Tables 7, 9 and 10) and reanalyse the model a large number of times.

Probabilistic sensitivity analyses of the base case were conducted by assuming a beta distribution for the probability of successful treatment outcome in the conservative management strategy (the 5-year probability of presenting for surgery being the complement of this). All cost parameters were assigned a gamma distribution as this distribution fits the skewed nature found in resource use and cost data. For health-care resource group inpatient unit cost data, the interquartile range was used to derive the standard error. For the normal distribution this is defined by the interval ± 0.67 standard errors either side of the mean.\textsuperscript{133} An estimate of the cost standard error was derived by generating the difference between the interquartile ranges and dividing it by 2 then multiplying by 0.6, where 0.67 is the critical value which excludes 50% of the standard normal distribution. There was no distribution attached to all-cause mortality rate as the estimate was derived from the general population. The utility parameters were

<table>
<thead>
<tr>
<th>TABLE 10 Quality-of-life estimates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health state</td>
</tr>
<tr>
<td>Symptom-free post-laparoscopic cholecystectomy</td>
</tr>
<tr>
<td>Symptom-free post-conservative management</td>
</tr>
<tr>
<td>Post-cholecystectomy syndrome</td>
</tr>
<tr>
<td>People with persistent symptoms</td>
</tr>
<tr>
<td>Symptoms not resolved in conservative management</td>
</tr>
<tr>
<td>People undergoing corrective surgery</td>
</tr>
</tbody>
</table>
assigned a beta distribution to take into account the constraints in terms of their construction, which is infinity at the lower end (worst possible health) and 1.0 at the upper end (perfect health).

Sensitivity analyses varied the assumptions and/or parameter point estimates applied in the base-case analysis. One-way sensitivity analyses (varying the probabilities, costs and QALY weights one at a time) were performed.

The probability of people needing surgery after conservative management
The probability of the number of people needing surgery was varied by 25% as the results of the systematic review suggested that between 25% and 75% of people needed surgery after conservative management.

Probability of complications during surgery
Waiting lists are a common tool for managing access to elective surgery. In the UK, the average reported time from referral by general practitioner to treatment for gallbladder problems varies greatly in different health trusts, from 5 to 18 weeks. There is little evidence on the health impact of delaying surgery for various conditions. According to cholecystectomy guidelines, conversion from laparoscopic to open cholecystectomy is halved (8% vs. 16%) when operating in the acute phase of the disease as opposed to allowing the acute phase to settle and being operated on later. The probability of surgical complications varies between 5% and 20%.

Cost of conservative management
There are no reliable data on the number of visits that people with symptoms of gallstone disease make to primary care providers before they are referred to a consultant, although it has been suggested that they may have multiple visits to their GP during the time they are awaiting treatment. The base-case analysis assumed that people with symptomatic gallstones had one primary care and one consultant visit. The number of visits was doubled to estimate the impact on cost-effectiveness. Another sensitivity analysis explored the inclusion of inpatient costs in the conservative management arm. According to the commissioner’s guide to cholecystectomy, it is not uncommon for a person to be readmitted as an emergency with a flare of symptoms three times during a prolonged period waiting for surgery. A Canadian study on the risk of emergency while waiting for elective cholecystectomy reported that 6.7% of participants had emergency admissions. Therefore, we estimated the cost of one, two and three additional inpatient stays for people who had persistent pain attacks while receiving conservative management. Further analysis was also performed assuming that all symptomatic people receiving conservative management had 1–3 non-elective episodes of short inpatient stay.

Utilities
As mentioned earlier, the data on utilities were based on published data and assumptions were made about the utility value of people who had received medical management. Although the RCTs included in the review of clinical effectiveness collected information on the number of pain attacks (within a pre-specified range) over a 5-year follow-up period, no data were provided on the duration of the pain attacks or on the number of pain attacks in each randomised group. Bass and colleagues estimated people preference values for selected outcomes by described frequency of pain or duration of outcome and their values ranged from 0.62 for having biliary pain once a day for a lifetime to 0.85 for having biliary pain once a week for 1 month. The CIs for these values spanned between 0.26 and 1.0 (full health).

Therefore, the utility of people that remained symptomatic in the conservative management arm was increased and decreased by 0.05 increments to explore the impact of this change on the results. Standard gamble utility weights for those who had open cholecystectomy with and without complications such as post-operative wound infections ranged from 0.57 to 0.83 for those with post-operative bile duct stone. Analysis was also performed to estimate the impact of increasing the utility of people who had continuing surgical complications from 0.64 to 0.80 (closer to the utility value of those patients who had open cholecystectomy 0.78).
Annual discount rate

The NICE guidelines recommend an annual discount rate of 3.5% for costs and outcomes and was applied in the base-case analysis. A range of between 0% and 6% was considered in the sensitivity analyses.

Increasing follow-up to 10 years

Evidence from the long-term follow-up studies suggests that the number of people seeking further treatment reduces over time, so the base-case analysis considered the 5-year follow-up. A sensitivity analysis was performed to explore how the small variation in modelled health outcomes and ongoing management costs (at 5 years) influences cost-effectiveness over a longer time horizon (10 years).

Value of information analysis

The decisions related to the adoption or rejection of technologies should be based on expected cost-effectiveness given the current existing information. However, the decisions should not be based on little, or poor-quality evidence, as long as the decision to conduct further research to support adoption (or rejection) is made simultaneously. Decisions to adopt or reject a technology based on existing information will be uncertain as there will always be a chance that the wrong decision could be made. Wrong decisions lead to opportunity costs due to forgone health benefits and resources. The expected cost of uncertainty is determined jointly by the probability that a decision based on existing information will be wrong and the consequences of a wrong decision. The estimates of the probability of error and opportunity costs of error can be used to calculate the expected cost of uncertainty or the expected loss surrounding the decisions. The expected cost of uncertainty can be interpreted as the expected value of perfect information (EVPI) and perfect information can be used to eliminate the possibility of making the wrong decision. We performed a value of information analysis to estimate the distribution of expected costs and expected QALYS of treatment of biliary pain/cholecystitis dependent on the uncertainty in the input parameters. The net monetary benefit (NMB) for the two strategies from each Monte Carlo iteration was computed to represent the possible values of NMB for all the possible realisations of the uncertain parameters. The maximum NMB among all the strategies was then calculated to determine the total EVPI per subject. The expected value of a decision undertaken with perfect information was derived by averaging the maximum net benefit with perfect information and the maximum net benefit with the current information. We then estimated the expected value for the entire population that could potentially benefit from more research (population EVPI). To calculate the population EVPI, we assumed the effective lifetime of the treatment to be 10 years. Benefits to future people were discounted at 3.5%. The annual patient population that could benefit from the results of a future study was based on the number of people undergoing a gallbladder excision per annum in England (Hospital Episode Statistics data), multiplied by the time period of 10 years.

Results

Deterministic and probabilistic results

The cost-effectiveness analysis aggregates the average 5-year costs for the treatments and time spent in each of the various health states of the model. Table 11 shows the results for the base-case analysis for a hypothetical cohort of 51-year-old women with symptomatic gallstones. The table reports the performance of surgery compared with conservative management, which is less costly and less effective. On average, conservative management care pathway costs less but has lower benefits (QALYs) than the surgery pathway. Analysis performed using a cohort of 51-year-old men had lower QALYs (4.108 for conservative management and 4.21 for cholecystectomy) but the ICER was similar to that of the base-case analysis (ICER £12,178).

Probabilistic results

To account for the uncertainty surrounding ICER (for surgery vs. conservative management) resulting from the joint uncertainty surrounding all the model input parameters, probabilistic sensitivity analysis using Monte Carlo simulations was performed. The results of the probabilistic analysis are reported in the form
of CEACs (Figure 28). The conservative management arm has a higher probability of being considered cost-effective for thresholds below £20,000 and the surgery arm has a higher probability of being considered cost-effective as the threshold increases beyond £20,000.

**Sensitivity analyses**

**Probability of the number of people needing surgery**

As anticipated, the value of the ICER doubles when we reduce the probability of people needing surgery after conservative management to 25%, as the costs of conservative management are reduced and its effectiveness increases (although the QALYs are still lower than those of the surgery strategy). This is equivalent to conservative management being targeted on a lower risk group (i.e. a group who have less frequent symptoms and better QoL than the average observed within the cohort).

On the other hand, the value of the ICER is reduced when the probability of people needing surgery after conservative management increases to 75%. The cost difference between the two strategies reduces but the difference between the QALYs increases, hence, making the surgery strategy more favourable (Table 12).

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Costs (£)</th>
<th>Incremental cost</th>
<th>QALYs</th>
<th>Incremental QALYs</th>
<th>ICER (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CM</td>
<td>1104</td>
<td></td>
<td>4.139</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.232</td>
<td>0.094</td>
<td>13,205</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Threshold value</th>
<th>10,000</th>
<th>20,000</th>
<th>30,000</th>
<th>40,000</th>
<th>50,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>CM</td>
<td>60%</td>
<td>51%</td>
<td>46%</td>
<td>44%</td>
<td>42%</td>
</tr>
<tr>
<td>Surgery</td>
<td>40%</td>
<td>49%</td>
<td>54%</td>
<td>56%</td>
<td>58%</td>
</tr>
</tbody>
</table>

CM, conservative management.

**FIGURE 28** Cost-effectiveness acceptability curve determined by society’s willingness to pay for an additional QALY. CM, conservative management.
Probability of complications during surgery
The results of varying the probability of complications between 0.05 and 0.20 produced similar results to those of the base case. The cost of conservative management was lower than surgery, but QALYs were also lower (Table 13).

Cost of conservative management
The ICER value reduced as the number of inpatient stays (under conservative management) increased (Table 14). When all the people that had symptoms in the conservative management strategy had an inpatient stay there was more than 50% chance of the surgery arm being considered to be cost-effective for the thresholds above £5000.

Changes in the number of outpatient and GP visits had very little impact on the results.

Utilities
The ICER results were sensitive to the utility values applied (Table 15). When we assumed that the utility decrement for people who remain symptomatic under conservative management was greater than in the base case, the ICER reduced in favour of surgery (this is as expected, as there is more potential for health improvement if one’s utility value is lower). However, for values above the base case, the results favour conservative management as QALY gains with surgery decrease.

The analyses which we performed to estimate the impact of increasing the utility of people who had continuing surgical complications had a low impact on the overall results. On average, both surgery costs and benefits were higher, and led to a slightly lower ICER than that of the base-case analysis (£14,761).

Annual discount rate for costs and benefits
Varying the discount rate for costs did not change the results substantially (Table 16). However, the ICERS appeared to vary more when the utility discount rate was changed. As expected, the ICER increased as the rates increased.
**TABLE 13** Cost-effectiveness of conservative management vs. surgery: effect of varying the probability of surgical complications

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Costs (£)</th>
<th>Incremental cost (£)</th>
<th>QALYs</th>
<th>Incremental QALYs</th>
<th>ICER (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Probability of surgical complications is 0.05</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>1140</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2427</td>
<td>1287</td>
<td>4.233</td>
<td>0.094</td>
<td>13,739</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>39%</td>
<td>49%</td>
<td>48%</td>
<td>46%</td>
<td>44%</td>
</tr>
<tr>
<td>Surgery</td>
<td>61%</td>
<td>51%</td>
<td>52%</td>
<td>54%</td>
<td>56%</td>
</tr>
</tbody>
</table>

| **Probability of surgical complications is 0.20** | | | | | |
| CM             | 1034      | –                    | 4.138 | –                 | –       |
| Surgery        | 2166      | 1133                 | 4.231 | 0.093             | 12135   |
| **Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)** | | | | | |
| Threshold value | 10,000    | 20,000               | 30,000| 40,000            | 50,000  |
| CM             | 59%       | 50%                  | 47%   | 45%               | 44%     |
| Surgery        | 41%       | 50%                  | 53%   | 55%               | 56%     |

CM, conservative management.

**TABLE 14** Cost-effectiveness of conservative management vs. surgery assuming individuals have an inpatient stay

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Costs (£)</th>
<th>Incremental cost (£)</th>
<th>QALYs</th>
<th>Incremental QALYs</th>
<th>ICER (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assuming that the people with persistent pain had one inpatient stay</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>1455</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>885</td>
<td>4.232</td>
<td>0.094</td>
<td>9455</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>54%</td>
<td>48%</td>
<td>45%</td>
<td>43%</td>
<td>43%</td>
</tr>
<tr>
<td>Surgery</td>
<td>46%</td>
<td>52%</td>
<td>55%</td>
<td>57%</td>
<td>57%</td>
</tr>
<tr>
<td><strong>Assuming that the people with persistent pain had two inpatient stays</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>1807</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>533</td>
<td>4.232</td>
<td>0.094</td>
<td>5700</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>48%</td>
<td>44%</td>
<td>43%</td>
<td>42%</td>
<td>41%</td>
</tr>
<tr>
<td>Surgery</td>
<td>52%</td>
<td>56%</td>
<td>57%</td>
<td>58%</td>
<td>59%</td>
</tr>
<tr>
<td><strong>Assuming that the people with persistent pain had three inpatient stays</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>2158</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>182</td>
<td>4.232</td>
<td>0.094</td>
<td>1950</td>
</tr>
</tbody>
</table>
### TABLE 14 Cost-effectiveness of conservative management vs. surgery assuming individuals have an inpatient stay

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Costs (£)</th>
<th>Incremental cost (£)</th>
<th>QALYs</th>
<th>Incremental QALYs</th>
<th>ICER (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>43%</td>
<td>41%</td>
<td>40%</td>
<td>40%</td>
<td>40%</td>
</tr>
<tr>
<td>Surgery</td>
<td>57%</td>
<td>59%</td>
<td>60%</td>
<td>60%</td>
<td>60%</td>
</tr>
<tr>
<td><strong>Assuming that all the people with symptoms had one inpatient stay</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>2223</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>117</td>
<td>4.232</td>
<td>0.094</td>
<td>1253</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>42%</td>
<td>40%</td>
<td>40%</td>
<td>39%</td>
<td>39%</td>
</tr>
<tr>
<td>Surgery</td>
<td>58%</td>
<td>60%</td>
<td>60%</td>
<td>61%</td>
<td>61%</td>
</tr>
</tbody>
</table>

CM, conservative management.

### TABLE 15 Cost-effectiveness of conservative management vs. surgery assuming different utility values for individuals who remain symptomatic in conservative management

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Costs (£)</th>
<th>Incremental cost (£)</th>
<th>QALYs</th>
<th>Incremental QALYs</th>
<th>ICER (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assuming that the utility of those who remain symptomatic in conservative management is 0.60</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>3.936</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.232</td>
<td>0.296</td>
<td>4175</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>14%</td>
<td>8%</td>
<td>7%</td>
<td>7%</td>
<td>7%</td>
</tr>
<tr>
<td>Surgery</td>
<td>68%</td>
<td>92%</td>
<td>93%</td>
<td>93%</td>
<td>93%</td>
</tr>
<tr>
<td><strong>Assuming that the utility of those who remain symptomatic in conservative management is 0.65</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>3.995</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.232</td>
<td>0.237</td>
<td>5212</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>20%</td>
<td>12%</td>
<td>10%</td>
<td>10%</td>
<td>9%</td>
</tr>
<tr>
<td>Surgery</td>
<td>80%</td>
<td>88%</td>
<td>90%</td>
<td>90%</td>
<td>91%</td>
</tr>
<tr>
<td><strong>Assuming that the utility of those who remain symptomatic in conservative management is 0.70</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.054</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.232</td>
<td>0.178</td>
<td>6936</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>28%</td>
<td>18%</td>
<td>15%</td>
<td>14%</td>
<td>14%</td>
</tr>
<tr>
<td>Surgery</td>
<td>72%</td>
<td>82%</td>
<td>85%</td>
<td>86%</td>
<td>86%</td>
</tr>
</tbody>
</table>

**continued**
TABLE 15 Cost-effectiveness of conservative management vs. surgery assuming different utility values for individuals who remain symptomatic in conservative management (continued)

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Costs (£)</th>
<th>Incremental cost (£)</th>
<th>QALYs</th>
<th>Incremental QALYs</th>
<th>ICER (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assuming that the utility of those who remain symptomatic in conservative management is 0.75</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.113</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.232</td>
<td>0.119</td>
<td>10,365</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>40%</td>
<td>26%</td>
<td>22%</td>
<td>21%</td>
<td>20%</td>
</tr>
<tr>
<td>Surgery</td>
<td>60%</td>
<td>74%</td>
<td>78%</td>
<td>79%</td>
<td>80%</td>
</tr>
<tr>
<td><strong>Assuming that the utility of those who remain symptomatic in conservative management is 0.85</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.231</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.232</td>
<td>0.001</td>
<td>906528</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>79%</td>
<td>55%</td>
<td>47%</td>
<td>44%</td>
<td>42%</td>
</tr>
<tr>
<td>Surgery</td>
<td>21%</td>
<td>45%</td>
<td>53%</td>
<td>56%</td>
<td>58%</td>
</tr>
<tr>
<td><strong>Assuming that the utility of those who remain symptomatic in conservative management is 0.90</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.29</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.232</td>
<td>–0.058</td>
<td>Dominated</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>96%</td>
<td>82%</td>
<td>71%</td>
<td>65%</td>
<td>62%</td>
</tr>
<tr>
<td>Surgery</td>
<td>4%</td>
<td>18%</td>
<td>29%</td>
<td>35%</td>
<td>38%</td>
</tr>
<tr>
<td><strong>Increasing utility of those that had complications to 0.93</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.138</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.223</td>
<td>0.085</td>
<td>14549</td>
</tr>
<tr>
<td><strong>Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold value</td>
<td>10,000</td>
<td>20,000</td>
<td>30,000</td>
<td>40,000</td>
<td>50,000</td>
</tr>
<tr>
<td>CM</td>
<td>61%</td>
<td>53%</td>
<td>49%</td>
<td>47%</td>
<td>46%</td>
</tr>
<tr>
<td>Surgery</td>
<td>39%</td>
<td>47%</td>
<td>51%</td>
<td>53%</td>
<td>54%</td>
</tr>
</tbody>
</table>

CM, conservative management.
### TABLE 16  Cost-effectiveness of conservative management vs. surgery: effect of varying annual discount rates

<table>
<thead>
<tr>
<th>Discount rate</th>
<th>Strategy</th>
<th>Cost (£)</th>
<th>Incremental cost (£)</th>
<th>QALYs</th>
<th>Incremental QALYs</th>
<th>ICER (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sensitivity analysis varying the cost discount rate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0%</td>
<td>CM</td>
<td>1185</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2350</td>
<td>1165</td>
<td>4.232</td>
<td>0.094</td>
<td>12,454</td>
</tr>
<tr>
<td>1%</td>
<td>CM</td>
<td>1161</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2347</td>
<td>1186</td>
<td>4.232</td>
<td>0.094</td>
<td>12,678</td>
</tr>
<tr>
<td>2%</td>
<td>CM</td>
<td>1138</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2344</td>
<td>1207</td>
<td>4.232</td>
<td>0.094</td>
<td>12,894</td>
</tr>
<tr>
<td>3%</td>
<td>CM</td>
<td>1115</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2342</td>
<td>1226</td>
<td>4.232</td>
<td>0.094</td>
<td>13,103</td>
</tr>
<tr>
<td>4%</td>
<td>CM</td>
<td>1094</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2339</td>
<td>1245</td>
<td>4.232</td>
<td>0.094</td>
<td>13,306</td>
</tr>
<tr>
<td>5%</td>
<td>CM</td>
<td>1073</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2336</td>
<td>1264</td>
<td>4.232</td>
<td>0.094</td>
<td>13,502</td>
</tr>
<tr>
<td>6%</td>
<td>CM</td>
<td>1052</td>
<td>–</td>
<td>4.139</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2334</td>
<td>1281</td>
<td>4.232</td>
<td>0.094</td>
<td>13,691</td>
</tr>
<tr>
<td><strong>Sensitivity analysis varying the benefit (QALYs) discount rate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0%</td>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.371</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.522</td>
<td>0.15</td>
<td>8220</td>
</tr>
<tr>
<td>1%</td>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.301</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.435</td>
<td>0.134</td>
<td>9230</td>
</tr>
<tr>
<td>2%</td>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.234</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.352</td>
<td>0.118</td>
<td>10,505</td>
</tr>
<tr>
<td>3%</td>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.17</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.271</td>
<td>0.102</td>
<td>12,168</td>
</tr>
<tr>
<td>4%</td>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.109</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.194</td>
<td>0.086</td>
<td>14,430</td>
</tr>
<tr>
<td>5%</td>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>4.05</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.12</td>
<td>0.07</td>
<td>17,689</td>
</tr>
<tr>
<td>6%</td>
<td>CM</td>
<td>1104</td>
<td>–</td>
<td>3.994</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>2340</td>
<td>1236</td>
<td>4.049</td>
<td>0.054</td>
<td>22,797</td>
</tr>
</tbody>
</table>

CM, conservative management.
Increasing follow-up to 10 years
The results moved in the same directions as those of the base-case analysis as the probability of getting surgery in the conservative management strategy only increased by 0.01. The evidence from the systematic review of clinical effectiveness indicated that there was only one additional person that received surgery from the conservative management arm in the 14-year follow-up period bringing the total to 46 out of 102 (45%). There was quite a substantial drop in QALY gain over the longer follow-up period (Table 17). This was probably because, after 5 years, people on conservative management were no longer symptomatic.

Value of information
The probabilistic analysis indicated that, for a threshold of £30,000, surgery had a 57% chance of being considered cost-effective. The expected saving from perfect information per person was £585.91 and the expected gain in effectiveness was 0.054 per person. The per person EVPI was £2209.65 and the resulting population EVPI was £1,206,730,653.

### Table 17: Cost-effectiveness of conservative management vs. surgery: effect of increasing the follow-up to 10 years

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Costs (£)</th>
<th>Incremental cost (£)</th>
<th>QALYs</th>
<th>Incremental QALYs</th>
<th>ICER (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CM</td>
<td>1275</td>
<td>–</td>
<td>7.645</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Surgery</td>
<td>2436</td>
<td>1161</td>
<td>7.707</td>
<td>0.062</td>
<td>18,628</td>
</tr>
</tbody>
</table>

### Probability cost-effective for different threshold values for society’s willingness to pay for a QALY (£)

<table>
<thead>
<tr>
<th>Threshold value</th>
<th>10,000</th>
<th>20,000</th>
<th>30,000</th>
<th>40,000</th>
<th>50,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>CM</td>
<td>62%</td>
<td>54%</td>
<td>51%</td>
<td>49%</td>
<td>48%</td>
</tr>
<tr>
<td>Surgery</td>
<td>38%</td>
<td>46%</td>
<td>49%</td>
<td>51%</td>
<td>52%</td>
</tr>
</tbody>
</table>

CM, conservative management.
Chapter 6 Discussion

This assessment sought to answer the following research question posed by the UK National Institute for Health Research Health Technology Assessment programme: What is the clinical effectiveness and cost-effectiveness of cholecystectomy for preventing recurrent symptoms and complications from symptomatic gallstones or cholecystitis?

Summary of findings

This assessment, using the best available evidence and a health economic model, found that conservative management is on average less costly than surgery but also less effective for treating symptomatic gallstones. The results of the economic evaluation were most sensitive to the utility values used for people who were managed conservatively. The conservative management strategy dominated surgery (i.e. the conservative management was cheaper and more effective) when the utility value for persistent symptoms was assumed to be 0.90. However, when the utility value equalled 0.60, surgery was more effective, although more expensive, giving an ICER of £4175. With changes in the utility value of persistent symptoms from 0.60 to 0.90, the probability of the surgery strategy being considered cost-effective at a willingness-to-pay threshold of £20,000 changed from 92% to 18%. However, caution should be exercised owing to the uncertainty around some of the parameters used in the model. The findings of the clinical effectiveness review indicate that symptomatic people randomised to observation were at significantly greater risk of experiencing gallstone-related complications (in particular, acute cholecystitis), pain attacks and admissions to hospital for gallstone-related pain. Symptomatic people randomised to surgery were significantly more likely to undergo surgery and had a greater risk of experiencing surgery-related complications as well as minor complications. Forty-five per cent of people originally randomised to observation switched to surgery, whereas 12% of people originally randomised to surgery avoided the operation. It is interesting that nearly half of people randomised to observation were not operated on during the long-term follow-up period, demonstrating that there are a proportion of people who do not require surgery. When we considered outcomes according to the treatment people actually received, we noticed that people who did not undergo surgery had fewer episodes of pain attacks and fewer admissions to hospital as a result of pain than people who were treated with cholecystectomy.

Approximately 70,000 cholecystectomies are performed every year in the UK, the majority laparoscopically. However, surgery could be avoided in a proportion of people with symptoms but no complications, and this option appears to be safe in terms of subsequent events. The implications of this assessment in terms of planning the best care pathway for people suffering from gallstone disease are therefore crucial.

Clinical effectiveness

The two included studies46,113 we identified in the current literature were good-quality RCTs, which randomised a total of 201 participants with symptomatic gallstone disease to either cholecystectomy or observation. Both trials reported relevant outcomes, which were combined in mathematical syntheses when appropriate. It is noteworthy that both trials were conducted in Norway and not in the UK. We do not know how well the health-care system in Norway mirrors the UK NHS.

Gallstone disease associated events

On the whole, significantly more people randomised to observation (14%) than to surgery (2%) experienced gallstone-related complications. New events that occurred in the observation group were acute cholecystitis, common bile duct stones and acute pancreatitis. In particular, further complications occurred more frequently (27%) in people with an initial diagnosis of acute cholecystitis46 than in those (1%) with uncomplicated symptomatic gallstones (biliary pain only).113 Few people suffered from CBD stones during the 14-year follow-up with no significant difference between intervention groups.
(4% in the observation group vs. 1% in the surgery group). In particular, CBD stones occurred in only one person with uncomplicated symptomatic gallstones (biliary pain only) rather than acute cholecystitis during the 14-year follow-up period. Similarly, the proportion of people suffering from acute pancreatitis was the same in both intervention groups (1% observation group vs. 1% in the surgery group). These findings are in line with those of early natural history studies which report a cumulative rate of 2–6% for CBD stones or acute pancreatitis in participants observed for 5–10 years.17,42,92 The overall risk of developing acute biliary complications in people with symptomatic gallstones has been estimated to be around 3% per annum during an observation period of 6 years.143 In a recent population-based study,12 gallstone-related complications were observed in 7.5% and 22% of mild and severe symptomatic people, respectively. In short, in the included RCTs, the majority of people treated conservatively did not experience long-term complications (86%); CBD stones and episodes of acute pancreatitis were both rare.

**Pain attacks**

Overall, the proportion of people suffering from pain attacks was not significantly different between randomised groups (25% in the observation group vs. 12% in the surgery group). Pain attacks were observed more frequently in participants treated conservatively (26/102 people) than in those who underwent surgery (12/99 people) and in participants with uncomplicated symptomatic gallstones (biliary pain only – 23/69 people) rather than in those with an initial diagnosis of acute cholecystitis (3/33). The admissions to hospital as a result of pain were not significantly different between intervention groups. However, admissions were more frequently observed in people with uncomplicated symptomatic gallstones (biliary pain only – 12/69) rather than in those with acute cholecystitis (4/33). It is noteworthy that, when we considered people with gallstones according to the treatment they actually received and not according to randomisation, fewer episodes of pain were observed in people treated conservatively (12/68) than in those who were eventually operated on (26/133).

The review findings on pain attacks are broadly similar to those suggested in the clinical literature, i.e. cholecystectomy is not always successful in relieving symptomatic people from pain. Up to 40% of people may suffer from post-cholecystectomy symptoms.56 Symptoms may persist or arise de novo after surgery.56 Marked biliary pain has been described in 4–9% of people after cholecystectomy, while persistent abdominal pain or non-specific pain has been reported in about 13–37% of people.57-62 Some investigators have also reported a persistent pain similar to that experienced pre-operatively in approximately 20% of people after cholecystectomy.64,65

**Surgery rate**

The majority of people randomised to receive surgery (88%) and approximately half of the people randomised to observation (45%) eventually underwent cholecystectomy during the 14-year follow-up period. As few gallstone-related complications were experienced by symptomatic people randomised to observation, it is likely that pain was the reason why they underwent surgery.114 Most of the surgical procedures were performed during the first 5 years and virtually no operations occurred after 5 years. These data are in accordance with previously published studies. McSherry and colleagues17 found that 44% of people with mild gallstone disease underwent surgery during a 5-year follow-up period. Similarly, Festi and colleagues12 reported that 17% and 41% of people with mild and severe symptoms, respectively, underwent surgery during a 10-year follow-up period, but the majority of the surgical procedures (68%) were performed during the first 4 years.

Not all participants in the observation group required cholecystectomy or experienced severe complications during the long-term follow-up. Interestingly, 55% of people randomised to observation did not require an operation during the 14-year follow-up period and 12% of people randomised to receive cholecystectomy did not undergo the scheduled operation, probably as a result of minimal, tolerable symptoms. These findings are in agreement with those of early natural history studies17,45 and with those of more recent observational and population-based studies.12,56 Larsen and colleagues56 found that 45% of symptomatic people on watchful waiting were totally relieved of symptoms during a 1-year observation period. Similarly,
Festi and colleagues\textsuperscript{12} observed that 58\% of people with initially mild symptoms and 52\% of those with more severe symptoms did not experience further episodes of pain during a follow-up period of 10 years.

**Surgery associated events**

The risk of surgery-related complications including abdominal infection, bile leakage, wound infection, dehiscence and bile duct injury was significantly higher in the cholecystectomy group. Nineteen per cent of participants originally randomised to surgery, compared with 7\% participants randomised to observation (who were eventually operated on), experienced surgery-related complications. Complications of cholecystectomy have been well documented and the findings of our two RCTs\textsuperscript{46,113} are consistent with those of three recent Cochrane systematic reviews\textsuperscript{106,144,145} which indicate that the total number of people suffering complications after open, small-incision or laparoscopic cholecystectomy is high with no significant differences between the three surgical procedures.\textsuperscript{106} In particular, the proportions of total complications after laparoscopic and small-incision cholecystectomy calculated from 13 clinical trials at low risk of bias (total 2337 participants) were 17\% and 17.5\%, respectively.\textsuperscript{106}

**Mortality rate**

There were no deaths caused by gallstone disease in the included trials. The all-cause mortality at 14 years was greater (but not significantly greater) among participants randomised to surgery. Even though a significant difference between intervention groups was not detected, it is noteworthy that the relative risk was 0.73 (95\% CI 0.41 to 1.31) favouring the observation group. This finding suggests that people undergoing surgery had an increased probability of death compared with non-operated people. A clear explanation of this finding is difficult to determine. However, surgery in itself carries an intrinsic mortality risk, especially if there are pre-existing comorbidities.

**Quality of life**

We were not able to meta-analyse the scores of QoL scales. The trial investigators reported that, overall non-significant differences were observed between participants who underwent cholecystectomy and those treated conservatively, and no gallstone or surgery-related deaths occurred in the two randomised groups. Participants in both treatment groups experienced a decline over time in pain scores, and their QoL scores improved after randomisation. It is noteworthy that participants with more frequent and marked pain at randomisation were reported to have a higher probability of subsequent gallstone-related events. For the group with an initial diagnosis of acute cholecystitis, the trial investigators analysed the results according to the treatment participants actually received and unexpectedly did not find any difference between observed and operated participants. It is likely, however, that the sample size of the two groups (64 participants in total) was too small to detect statistically significant differences.

**Early compared with delayed surgery**

We identified only two RCTs in the current literature, which compared observation/conservative management with cholecystectomy. Several RCTs have been conducted on the effects and safety of early compared with delayed surgery. Although these studies do not focus specifically on people with uncomplicated symptomatic gallstone disease or with a first episode of biliary pain presenting to secondary care, and the delayed period is relatively short (a few weeks), it is worth considering the outcomes of people allocated to ‘delayed surgery’ in terms of complications and need for emergency surgery in light of our review results. In particular, two Cochrane systematic reviews have been recently published on the effects of early laparoscopic cholecystectomy compared with delayed cholecystectomy in people with either acute cholecystitis or biliary pain.\textsuperscript{72,146}

The Cochrane systematic review on early laparoscopic cholecystectomy (less than 7 days from symptom onset) compared with delayed cholecystectomy (more than 6 weeks after initial admission) in people with an initial diagnosis of acute cholecystitis\textsuperscript{146} included five trials with a total of 451 participants. No statistically significant differences between the two groups were detected for any of the outcomes considered, including complication rate (bile duct injury odds ratio 0.6; 95\% CI 0.15 to 2.70) and
conversion to open cholecystectomy (odds ratio 0.85; 95% CI 0.53 to 1.34). Length of follow-up was not reported. However, 18% of the people randomised to the delayed group had non-resolution or recurrence of symptoms before their planned operation and, therefore, required emergency laparoscopic cholecystectomy. The proportion of these emergency procedures converted to open cholecystectomy was 45%.

The same authors conducted a systematic review to evaluate the benefits and harms of early compared with delayed laparoscopic cholecystectomy in participants with biliary pain due to gallstone disease. They identified only one trial with a total of 75 participants in the literature. Morbidity, and in particular severe morbidity (e.g. acute pancreatitis, bile duct injury, gallbladder perforation), was significantly lower in the early group (0%, 0/35) than in the delayed group (15%, 6/40). Overall, during the delayed period (mean 4.2 months) 35% of people in the delayed group (14/40) required 18 hospital admissions for symptoms related to gallstone disease (hospital admissions for people in the early group were not reported). Hospital stay was significantly shorter in the early group than in the delayed group (weighted mean difference −1.25 days; 95% CI −2.05 to −0.45). The trial was at high risk of bias (unclear allocation concealment, lack of blinding, no sample size calculation and no intention-to-treat analysis) hence its results can only be interpreted tentatively.

**Factors influencing the decision to undertake a cholecystectomy**

From a clinical point of view, the review findings suggest that it would be crucial to identify which characteristics of gallstone disease could predict the evolution of symptoms. In particular, it would be very important to be able to single out people with uncomplicated symptomatic gallstones who could be treated conservatively. Unfortunately, at present no definitive factors have been identified. Even the presence of pain in the upper right abdominal quadrant may not consistently be related to gallbladder stones and, overall, the symptoms caused by gallstone disease are still not completely understood, rendering it difficult to identify people who could benefit from surgery. Furthermore, people vary considerably in the way they report their symptoms depending on their individual pain threshold as well as their preference for having or avoiding surgery. At present, in many cases, surgery is offered independently from the clinical symptoms of people presenting with gallstone disease and without considering the potential benign course of the disease partly due to the wide diffusion of laparoscopic cholecystectomy. According to the World Gastroenterology Organisation Practice Guideline on gallstone disease, when a group of nine surgeons were asked to evaluate 252 people who underwent cholecystectomy, they agreed that surgery was the appropriate option in only 52% of cases and failed to find an agreement on 44% of cases. There is now an indication that removal of the gallbladder may also potentially lead to a slightly increased risk of colon cancer in women in the long term.

**Summary**

In our assessment, approximately half of the people in the observation group were eventually operated on. Almost no surgical operations were performed after the first 5 years of follow-up. Participants who underwent cholecystectomy experienced more surgery-related complications and showed a slight, non-significant, increase in mortality rate (all-cause mortality) than those who were treated conservatively. Conversely, participants in the observation groups had more episodes of cholecystitis, but the incidence of other gallstone-related complications (e.g. common bile duct stones, acute pancreatitis) was low. Approximately half of the people in the observation group did not required surgery at long-term indicating that there is probably a subgroup of people with symptomatic gallstone disease who could be safely treated conservatively.

**Summary of findings from the economic model**

The economic model was developed using evidence synthesis from three main sources: a systematic review and meta-analysis of clinical effectiveness, advice from clinical experts and a prior health state valuation survey. The economic model compared two treatment strategies: conservative management and surgery. The model compared cumulative costs and QALYs for a cohort of 51-year-old women for a 5-year time horizon. This time was chosen as the available data indicated that the results did not markedly change if a
longer-term horizon was adopted. On average, the surgery strategy cost £1236 more than the conservative management strategy but was, on average, more effective, and generated 0.094 additional QALYs. The incremental cost per QALY was £13,205. The incremental cost-effectiveness result indicated that the conservative management strategy had a 51% chance of being considered cost-effective at society’s willingness-to-pay threshold of £20,000. The probability of cost-effectiveness was not sensitive to changes in willingness to pay, when the threshold increased to £30,000, the conservative management strategy had a 46% chance of being considered cost-effective.

The result of the analysis using a male cohort aged 51 years was similar to that of the base-case analysis. On average, surgery cost more but was more clinically effective, even though the effectiveness for both arms was slightly lower (conservative management 4.108 and cholecystectomy 4.21) leading to an ICER of £12,718. This slight reduction in QALYs was the result of the higher mortality of the male cohort.

The results were sensitive to the probability of the number of people needing surgery in the conservative management strategy. The systematic review indicated that there was uncertainty around the estimate derived in the meta-analysis. On average, the cost of the conservative management strategy reduced to £694 when the probability was reduced to 25% leading to an ICER of £33,542 per QALY for the surgical strategy. The probability that the conservative management strategy would be considered cost-effective was between 56% and 61% (for willingness to pay for QALY values of £20,000–30,000, respectively). However, the ICER reduced to £4291 when the probability of surgery among those initially managed conservatively was increased to 75%. The probability that the surgery strategy would be considered cost-effective at the recommended threshold was between 51% and 53%.

There was no evidence to indicate that the risk of surgical intervention increased over time for patients that required surgery after conservative management. Therefore, these patients were assumed to follow a similar pathway to those who went straight into surgery. However, the model considered that patients who had surgery after conservative management had a lower utility prior to surgery – to take into account the fact that they remained symptomatic.

Evidence suggests that the number of complications from laparoscopic cholecystectomy has reduced over the years as the procedure has become widely used. The sensitivity analyses results around the probability of surgical complications were similar to those of the base-case analysis (£13,739 when probability of complications = 0.05, and £12,135 when probability of complications = 0.2), suggesting that the model is robust to the changes in the probability of surgical complications.

The results were more sensitive to changes in the costs of conservative management. As there are no data to support the average number of visits people may have to the GP and the hospital, various exploratory analyses were performed to assess the impact of additional inpatient stays for people in the conservative management strategy. As anticipated, as the number of inpatient stays (each year) for the group with persistent pain increased, the cost of the conservative management strategy increased, thereby reducing the cost difference between the two strategies. This led to a reduction of the ICER from £13,205 (no inpatient stay) to £1253 (three non-elective inpatient short stays).

The results were most sensitive to the utility value that was used for people who were managed conservatively. Based on a previous valuation survey, in the base-case analysis it was assumed that the utility was 0.71 among those with persistent symptoms and 0.80 for those with no persistent pain. As appropriate information on the number of pain attacks and their impact on QoL was not available from the trial data, these values could have been over- or underestimated, and were therefore scrutinised in sensitivity analysis. The ICERS varied from £4175 (when utility value equalled 0.60 for persistent symptoms), to conservative management strategy dominating surgery when the utility value for persistent symptoms was assumed to be 0.9. The probability of conservative management strategy being considered cost-effective for society’s willingness-to-pay thresholds of £20,000–30,000 ranged from 8% to 82%. With changes in the utility value of persistent symptoms from 0.60 to 0.90, the probability of the surgery strategy being considered
cost-effective at willingness-to-pay threshold of £20,000 changed from 92% to 18%. The results were not sensitive to changes in the utility of complications associated with surgery. The results were not markedly sensitive to changes in the discount rates applied to both the costs and the benefits.

**Strengths and limitations of the assessment**

The methods used to conduct this assessment were detailed and thorough. In particular, we performed comprehensive literature searches of the major electronic databases and we contacted experts in the field to identify all existing relevant evidence. We reviewed all potential eligible studies for inclusion and we did not restrict study selection to English-language publications. We assessed the methodological quality of included studies using the best recommended risk of bias tool. We developed specific data extraction forms on pre-specified outcome parameters and two reviewers independently extracted data from included studies. Despite all these efforts there is still the possibility that some relevant evidence remains buried in non-indexed journals or hidden as a result of non-publication.

We identified only two RCTs from the same investigators (published in six reports) in the current literature and no non-randomised comparative studies. Both trials, even though at low risk of bias, were of small sample size and it likely that they were underpowered to detect some important treatment differences between the interventions. Moreover, as a consequence of the small number of participants, few events were available for some of the analyses with wide confidence intervals around the estimates of treatment effect. It is also worth noting that even though statistical heterogeneity was not identified in the performed meta-analyses, the small sample sizes may have contributed to a lack of power to detect statistical heterogeneity.

The two trials did not include post-cholecystectomy symptoms within their outcome measurements. As cholecystectomy is supposed to completely cure gallstone symptoms, an important outcome to consider would have been the number of people who still experience pain post surgery. Similarly, little information was available on the type of ‘conservative’ management – in terms of regimen of medication and GP visits – for participants in the observation group. Even though ‘episodes of pain’ were recorded in both intervention groups in both trials, the severity of these episodes was not reported and uncertainty remains as to how these episodes were subsequently treated. Both trials reported the number of admissions to hospital as a result of pain but without providing details of what exactly ‘admission to hospital’ entailed.

We were able to contact one of the trials investigators who explained that in Norway, where the trials were conducted, participants who were admitted to hospital as a result of pain are commonly offered further imaging and laboratory tests to confirm the nature of the pain before opting for the best medical or surgical treatment. This is somewhat different from what happens in the UK where further admissions to hospital as a result of pain are normally treated by surgery, unless contraindicated.

Another limitation of this assessment is that both trials were conducted outside the UK and it is likely that their findings cannot be easily generalised to a UK clinical setting. Conservative management is not a policy that is (or has been) used in the NHS. As such, there was an inherent difficulty in extrapolating the review findings to the NHS setting. We addressed this difficulty by consulting with various clinical experts in the field. However, until prospective data are collected, the exact structure of a conservative management strategy in the NHS, in the UK, is unknown.

A major challenge in analysing and presenting the results of the included trials was the number of participants in the observation group who crossed over to receive surgery and similarly, although less numerous, the number of participants in the surgery group who refused to undergo the operation. We analysed the outcomes using an intention-to-treat approach (i.e. according to randomisation), which allows a proper comparison between treatment groups. However, when the number of participants who did not adhere to the intervention they were originally allocated to is so high, the overall validity of the results becomes questionable and their interpretation problematic. For this reason we decided to also use
an efficacy approach. We present the main results of the two trials according to the treatment participants actually received, regardless of randomisation (Figures 20–22 in Chapter 4). As this approach has the advantage of comparing the specific effects of surgery compared with those of pure observation, it does, however, violate randomisation and potentially introduce biases.

Modelling and estimation of cost-effectiveness were challenging because of the lack of data on many of the parameters required in the model. As indicated in Chapter 5, considerable effort was made to identify relevant data and sensitivity analyses were used to explore the impact of uncertainties. There were very few data on the conservative management strategy, as it is not practised in the UK and the modelling parameters were based on the best available data. Therefore, the findings of this study should be treated cautiously.

The effectiveness of treatment was measured in QALYs which were derived from different sources: a study published in the UK and a study from the USA that used standard gamble to estimate utility preferences for different health states. As there were no data relating to the QoL of people that do not receive surgery, it was assumed that the utility of people who did not progress to surgery in the conservative management strategy was similar to those that were cured by surgery. This decision was based on the clinical judgement that people who do not receive surgery are unlikely to be experiencing persistent symptoms and are likely to be ‘doing well’ under the conservative management approach.

Another assumption made in the model was that all people in the surgery strategy received surgery. Although there is evidence to suggest that a minority of people do not take up surgery when it is offered, this assumption was considered to reflect the current practice in the UK, as surgery is the recommended treatment for people presenting with uncomplicated symptomatic gallstones or cholecystitis.

People’s preferences regarding the utility or disutility associated with the delivery of conservative management relative to surgical treatment (e.g. treatment time, pre-operative anxiety, post-operative pain) were not explicitly taken into account. People may have preferences over these attributes. Those who considered the disutility of surgery to outweigh the symptoms they experience would likely not agree to the procedure. As such, this model applies only to people who are considering surgery as a potential treatment option. It may be that additional incorporation of these factors among this group would change the QALY estimates to some degree. Further research to elicit preferences for the process and outcomes of treatment may be useful to explore the impact of these preferences.

The economic model focused on costs to the NHS. However, there are no data on the number of pain relief medications that people may procure to take care of their symptoms. There is a need for a prospective follow-up of people who do not have surgery to have further insight regarding their health-seeking behaviour, particularly the number of times they visit their GP and other health-care providers for the management of uncomplicated symptomatic gallstone disease (biliary pain or cholecystitis).
Chapter 7 Conclusions

Implications for health care

Cholecystectomy, and in particular laparoscopic cholecystectomy, is still the standard treatment for symptomatic gallstone disease (biliary pain or cholecystitis). The main clinical indication for performing cholecystectomy is persistent or excruciating pain. The results of this assessment, although associated with some uncertainty, suggest that uncomplicated symptomatic gallstones may have a more benign natural course than previously assumed and it is likely that a proportion of patients may not require surgery in the long term and this seems to be safe in terms of subsequent events.

Cholecystectomy is more costly to the NHS because of the use of resources associated with surgery and the costs related to the treatment of post-surgery complications. Our modelling does show, however, that conservative treatment/observation fails to become a cost-effective option when a high proportion of people develop complications and require emergency surgery. A policy of surgery for all, as opposed to a policy of conservative management followed by surgery for people whose symptoms persist, is likely to be more costly but more effective, even though the difference between the two policies is modest. Owing to the current dearth of evidence for some of the relevant health states for gallstone disease and, consequently, the uncertainty around some utility values used in the model, the findings of our economic evaluation require a cautious interpretation.

At present, our information suggests that in many centres in the UK, cholecystectomy is the default option for all people with symptomatic gallstone disease with no attempts to identify people who might benefit from a conservative approach. Approximately 70,000 surgical procedures are performed every year in the UK and, in many hospitals, people are put on a waiting list and operated electively. However, conservative management may be a valid option in people presenting with uncomplicated symptoms (biliary pain or cholecystitis) depending on their age and sex, as well as on the clinical presentation of the disease and the evolution of symptoms over time. In addition, as uncomplicated symptoms are usually not urgent, it may be reasonable to take into consideration a non-surgical option first, alongside people’s personal preference and convenience. The recognition of symptoms related to gallstones remains, however, a main challenge in the management of the disease.

Suggested research priorities

The main gap in the current evidence is the dearth of randomised trials comparing cholecystectomy with observation/conservative management in uncomplicated, symptomatic gallstone disease, especially in the UK setting. For this assessment we identified only two RCTs, conducted in Norway, and we are not aware of any ongoing studies on this topic.

A large, good-quality, clinical trial needs to be undertaken to compare the effects and safety of conservative management with cholecystectomy in people presenting with uncomplicated symptomatic gallstones (biliary pain only) or cholecystitis. Ideally, such a trial would be multicentre, with long-term follow-up, would include a pre-specified assessment of people’s symptoms, relevant outcome measures, such as post-cholecystectomy symptoms and QoL measurements, and a full economic evaluation.
Areas in which further research would be important are the following:

- research based on well-designed clinical trials to compare the effects and safety of observation/conservative management with cholecystectomy in people presenting with uncomplicated symptomatic gallstones (biliary pain) or cholecystitis to secondary care
- research based on large, long-term, prospective cohorts or population studies to evaluate the natural history of symptomatic gallstone disease (including uncomplicated cases) in terms of frequency, characteristics of disease presentation, evolution of symptoms over time and clinical outcomes
- research to elicit factors that may predict the evolution of symptoms in people with symptomatic gallstone disease
- research on people’s personal preferences in terms of treatment options and outcomes
- research to identify resource use for people undergoing cholecystectomy (pre-operative assessment, surgical admissions, post-operative management) and for those receiving conservative management, in order to develop more robust cost estimates for the UK.
Acknowledgements

We are grateful to Lara Kemp for her secretarial support; Kieran Rothnie for contributing to the assessment of full-text papers; Graham Scotland for contributing to the checking of the economic model and for his comments on the draft of the cost-effectiveness chapter; Jonathan Cook for providing statistical advice; John Leeds (Consultant Gastroenterologist, Aberdeen Royal Infirmary) and Yuen Soon (Consultant Surgeon, Royal Surrey County Hospital) for providing clinical guidance as members of the advisory group for this assessment; Heather Peace for providing valuable consumer insight and advice through her participation as member of the advisory group for this assessment; and Karl Søndenaa, University of Bergen, Norway, for providing additional information and assisting with queries relating to the two included trials.

This report was commissioned by the National Institute for Health Research Health Technology Assessment programme as project number 12/16/01. The Health Services Research Unit and Health Economics Research Unit are core funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorates. The views and opinions expressed are those of the authors and do not necessarily reflect those of the funders.

Contribution of authors

Miriam Brazzelli (Senior Research Fellow) oversaw and co-ordinated all aspects of the assessment and wrote the original protocol.

Moira Cruickshank (Research Fellow) led the day-to-day running of the assessment and reviewed the evidence on the clinical effectiveness of the interventions.

Mary Kilonzo (Research Fellow) developed the care pathway for gallstone disease with clinical advice from Irfan Ahmed and conducted the economic evaluation with supervision from Paul McNamee (Professor of Health Economics).

Irfan Ahmed (Consultant Surgeon) and Alison Avenell (Clinical Professor of Health Services Research) provided expert advice on the clinical aspects and management of the disease.

Fiona Stewart (Information Specialist) developed and ran the search strategies with supervision from Cynthia Fraser (Senior Information Officer) and was responsible for obtaining full-text papers and for compiling the reference list of the report.

Andrew Elders provided statistical advice.

Craig Ramsay (Health Care Assessment Programme Director) jointly co-ordinated the assessment, led and co-ordinated the expert advisory group participation, and commented on the draft version of the report.

The authors of the draft version report were as follows: scientific summary, Miriam Brazzelli; background, Miriam Brazzelli and Moira Cruickshank; definition of the decision problem, Miriam Brazzelli; methods, Moira Cruickshank, Fiona Stewart, Andrew Elders and Miriam Brazzelli; clinical effectiveness, Moira Cruickshank, Andrew Elders and Miriam Brazzelli; cost-effectiveness, Mary Kilonzo and Paul McNamee; and discussion, Miriam Brazzelli, Mary Kilonzo; Conclusions: Miriam Brazzelli.

All authors commented on the draft of the report and approved its final version.
**Publication**

References


© Queen’s Printer and Controller of HMSO 2014. This work was produced by Brazzelliet al.under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.


REFERENCES


Appendix 1  Search strategies

Clinical effectiveness

Databases

MEDLINE (1946 to week 37, 2012)

MEDLINE In-Process & Other Non-Indexed Citations (10 September 2012)

EMBASE (1974 to 10 September 2012)

Ovid multfile search URL: http://shibboleth.ovid.com/

Search terms

1. cholecystitis/
2. cholecystitis, acute/
3. cholecystolithiasis/
4. gallstones/
5. cholelithiasis/
6. biliary colic/
7. (gall?bladder adj3 (empyema or inflam$)).tw.
8. (biliary colic or gall?stone$ or cholecystitis or cholecystolithiasis).tw.
9. ((pain or biliary symptom$) adj5 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
10. or/1-9
11. exp Cholecystectomy/
12. cholecystectom$.tw.
14. (((surgery or surgical) adj5 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
15. or/11-14
16. exp clinical trial/
17. randomized controlled trial.pt.
18. controlled clinical trial.pt.
19. randomi?ed.ab.
20. randomly.ab.
21. trial.ab.
22. placebo.ab.
23. drug therapy.fs.
24. groups.ab.
25. comparative study/ use prmz
26. (prospective$ or retrospective$).tw.
27. (compare$ or compara$).ti,ab.
28. or/16-27
29. 10 and 15 and 28
30. (review or editorial or case report$ or letter).pt.
31. exp animals/ not humans/
32. 29 not (30 or 31)
33. limit 32 to yr="1980 -Current"
34. limit 33 to yr="2000 -Current"
35. limit 33 to yr="1980-1999"
36. remove duplicates from 34
37. remove duplicates from 35
38. 36 or 37

The Cochrane Library (date of inception to September 2012)
URL: www.thecochranelibrary.com

Search terms

1. MeSH descriptor **Cholecystitis, Acute**, this term only
2. MeSH descriptor **Cholecystitis**, this term only
3. MeSH descriptor **Cholecystolithiasis**, this term only
4. MeSH descriptor **Gallstones**, this term only
5. MeSH descriptor **Cholelithiasis**, this term only
6. (gall*bladder) near/3 (empyema or inflam*)
7. biliary colic or gall*stone* or cholecystitis or cholecystolithiasis
8. (pain or biliary symptom*) near/5 (cholecystitis or cholecystolithiasis or gall*bladder)
9. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
10. MeSH descriptor **Cholecystectomy** explode all trees
11. cholecystectomy*
12. (excis* or remov*) near/4 (gall*bladder)
13. (surgery or surgical) near/5 (cholecystitis or cholecystolithiasis or gall*bladder)
14. (#10 OR #11 OR #12 OR #13)
15. (#9 AND #14), from 1980 to 2012

Database of Abstract of Reviews of Effects – Health Technology Assessment – NHS Economic Evaluation Database (date of inception to September 2012)
Centre for Reviews and Dissemination URL: www.crd.york.ac.uk

Search terms

1. Medical subject heading (MeSH) DESCRIPTOR Cholecystitis
2. MeSH DESCRIPTOR Cholecystitis, Acute
3. MeSH DESCRIPTOR Cholecystolithiasis EXPLODE 2
4. MeSH DESCRIPTOR Cholelithiasis
5. MeSH DESCRIPTOR Gallstones
6. (gallbladder or gall bladder) adj3 (empyema or inflam*)
7. biliary colic or gallstone* or gall stone* or cholecystitis or cholecystolithiasis
8. (pain or biliary symptom*) adj5 (cholecystitis or cholecystolithiasis or gallbladder or gall bladder)
9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
10. MeSH DESCRIPTOR Cholecystectomy EXPLODE 1
11. cholecystectomy*
12. (excis* or remov*) adj4 (gallbladder or gall bladder)
13. (surgery or surgical) adj5 (cholecystitis or cholecystolithiasis or gallbladder or gall bladder)
14. #10 OR #11 OR #12 OR #13
15. #9 and #14
Science Citation Index (1970 to 12 September 2012)

Conference Proceedings Citation Index – Science (1990 to 12 September 2012)
URL: www.isiknowledge.com

Search terms

1. TS =(cholecystitis or cholecystolithiasis or gallstones or cholelithiasis or biliary colic)
2. TS=((gall-bladder or gall*bladder or gallbladder) near/3 (empyema or inflam*))
3. TS=((gall-bladder or gall*bladder or gallbladder or cholecystitis or cholecystolithiasis) near/3 (pain or symptom*))
4. #3 OR #2 OR #1
5. TS=cholecystectom*
6. TS=((excis* or remov*) near/4 (gall-bladder or gall*bladder or gallbladder))
7. TS=((surgery or surgical) near/5 (cholecystitis or cholecystolithiasis or gall-bladder or gall*bladder or gallbladder))
8. #7 OR #6 OR #5
9. #8 AND #4
10. TS=(trial* or random* or comparison or compare or comparative or prospective or retrospective)
11. #10 AND #9
12. #11[excluding] Document Types=( LETTER OR EDITORIAL MATERIAL OR NOTE)
13. Timespan=1980-01-01 - 2012-09-12

Bioscience Information Service (1956 to 10 September 2011)
URL: www.isiknowledge.com

Search terms

1. TS =(cholecystitis or cholecystolithiasis or gallstones or cholelithiasis or biliary colic)
2. TS=((gall-bladder or gall*bladder or gallbladder) near/3 (empyema or inflam*))
3. TS=((gall-bladder or gall*bladder or gallbladder or cholecystitis or cholecystolithiasis) near/3 (pain or symptom*))
4. #3 OR #2 OR #1
5. TS=cholecystectom*
6. TS=((excis* or remov*) near/4 (gall-bladder or gall*bladder or gallbladder))
7. TS=((surgery or surgical) near/5 (cholecystitis or cholecystolithiasis or gall-bladder or gall*bladder or gallbladder))
8. #7 OR #6 OR #5
9. #8 AND #4
10. TS=(trial* or random* or comparison or compare or comparative or prospective or retrospective)
11. #10 AND #9
12. #11[excluding] Document Types=( LETTER OR EDITORIAL MATERIAL OR NOTE)
13. Timespan=1980-01-01 - 2012-09-12

Trials

Clinical Trials (date of inception to September 2012)
URL: http://clinicaltrials.gov/

Search terms
cholecystectomy AND (cholecystitis OR gallstones OR cholelithiasis OR biliary colic)
gallbladder removal AND (cholecystitis OR cholelithiasis)
World Health Organization Clinical Trials Registry (date of inception to September 2012)
URL: http://apps.who.int/trialsearch/

Search terms
(cholecystitis or gallstones) AND cholecystectomy

Current Controlled Trials (date of inception to September 2012)
URL: www.controlled-trials.com

National Institute for Health Research Portfolio (date of inception to September 2012)
URL: http://public.ukcrn.org.uk/search/

Conference proceedings from:
Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland.
Association of Laparoscopic Surgeons of Great Britain and Ireland.
British Society of Gastroenterology.

Cost-effectiveness

Databases

MEDLINE (1946 to 1 October 2012)

MEDLINE In-Process (8 October 2012)

EMBASE (1974 to 8 October 2012)
Ovid multifile search URL: http://shibboleth.ovid.com/

Search terms

1. cholecystitis/
2. cholecystitis, acute/
3. cholecystolithiasis/
4. gallstones/
5. cholelithiasis/
6. (gall?bladder adj3 (empyema or inflam$)).tw.
7. (biliary colic or gall?stone$ or cholecystitis or cholecystolithiasis).tw.
8. ((pain or biliary symptom$) adj5 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
9. or/1-8
10. exp *Cholecystectomy/
11. cholecystectomy$.ti.
13. ((surgery or surgical) adj3 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
14. or/10-13
15. exp "costs and cost analysis"/
16. economics/
17. exp economics,hospital/
18. exp economics,medical/
19. economics,pharmaceutical/
20. exp budgets/
21. exp models, economic/
22. exp decision theory/
23. ec.fs.
24. monte carlo method/
25. markov chains/
26. exp health status indicators/
27. cost$.ti.
28. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab.
29. economic$ model$.tw.
30. (economic$ or pharmacoeconomic$ or pharmaco-economic$).tw.
31. (price$ or pricing).tw.
32. (financial or finance or finances or financed).tw.
33. ((value adj2 money) or monetary).tw.
34. markov$.tw.
35. monte carlo.tw.
36. (decision$ adj2 (tree? or analy$ or model$)).tw.
37. (standard adj1 gamble).tw.
38. trade off.tw.
39. or/15-36
40. 9 and 14 and 39
41. exp animals/ not humans/
42. 40 not 41
43. remove duplicates from 42
44. limit 43 to yr="1980 -Current"

Science Citation Index (1970 to 10 October 2012)
Conference Proceedings Citation Index – Science (1990 to 10 October 2012)
URL: www.isiknowledge.com

Search terms

1. TS =(cholecystitis or cholecystolithiasis or gallstones or cholelithiasis or biliary colic)
2. TS=((gall-bladder or gall*bladder or gallbladder) near/3 (empyema or inflam*))
3. TS=((gall-bladder or gall*bladder or gallbladder or cholecystitis or cholecystolithiasis) near/3 (pain or symptom*))
4. #3 OR #2 OR #1
5. TS=cholecystectom*
6. TS=((excis* or remov*) near/4 (gall-bladder or gall*bladder or gallbladder))
7. TS=((surgery or surgical) near/5 (cholecystitis or cholecystolithiasis or gall-bladder or gall*bladder or gallbladder))
8. #7 OR #6 OR #5
9. #8 AND #4
10. TS=(economic* or cost* or price* or pricing* or financ* or markov* or monte carlo)
11. TS=(decision near/3 (tree* OR analy* OR model*))
12. #11 OR #10
13. #12 AND #9
14. Refined by: [excluding] Document Types=( LETTER OR EDITORIAL MATERIAL)
15. Timespan=1980-01-01 - 2012-10-10
NHS Economic Evaluation Database (date of inception to October 2012)
Centre for Reviews and Dissemination URL: www.crd.york.ac.uk

Search terms

1. MeSH DESCRIPTOR Cholecystitis
2. MeSH DESCRIPTOR Cholecystitis, Acute
3. MeSH DESCRIPTOR Cholecystolithiasis EXPLODE 2
4. MeSH DESCRIPTOR Cholelithiasis
5. MeSH DESCRIPTOR Gallstones
6. (gallbladder or gall bladder) adj3 (empyema or inflam*)
7. biliary colic or gallstone* or gall stone* or cholecystitis or cholecystolithiasis
8. (pain or biliary symptom*) adj5 (cholecystitis or cholecystolithiasis or gallbladder or gall bladder)
9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
10. MeSH DESCRIPTOR Cholecystectomy EXPLODE 1
11. cholecystectom*
12. (excis* or remov*) adj4 (gallbladder or gall bladder)
13. (surgery or surgical) adj5 (cholecystitis or cholecystolithiasis or gallbladder or gall bladder)
14. #10 OR #11 OR #12 OR #13
15. #9 and #14
16. * IN NHSEED
17. #9 AND #16
18. #14 AND #16
19. #17 OR #18

CEA Registry (date of inception to October 2012)
URL: https://research.tufts-nemc.org/cear4/SearchingtheCEARegistry/SearchtheCEARegistry.aspx

IDEAS (RePEc) (date of inception to October 2012)
URL: https://ideas.repec.org

Quality of life

Databases

MEDLINE (1946 to week 50 2012)
MEDLINE In-Process (10 December 2012)
EMBASE (1974 to 10 December 2012)
Ovid multofile search URL: http://shibboleth.ovid.com/

Search terms

1. Quality of life/
2. (euroqol or euro qol or eq5d or eq 5d).tw.
3. (sf36 or sf 36 or short form 36 or shortform 36).tw.
4. (sf6 or sf 6 or short form 6 or shortform 6).tw.
5. (sf12 or sf 12 or short form 12 or shortform 12).tw.
6. (sf16 or sf 16 or short form 16 or shortform 16).tw.
7. (sf20 or sf 20 or short form 20 or shortform 20).tw.
8. or/1,2-7
9. *cholecystitis/
10. *cholecystitis, acute/
11. *cholecystolithiasis/
12. *biliary colic/
13. (gall?bladder adj3 (empyema or inflam$)).tw.
14. (biliary colic or gall?stone$ or cholecystitis or cholecystolithiasis).tw.
15. ((pain or biliary symptom$) adj5 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
16. or/9-15
17. 8 and 16
18. (review or editorial or case report$ or letter or conference abstract).pt.
19. exp animals/ not humans/
20. 17 not (18 or 19)
21. cholecystitis/
22. cholecystitis, acute/
23. cholecystolithiasis/
24. gallstones/
25. cholelithiasis/
26. (gall?bladder adj3 (empyema or inflam$)).tw.
27. (biliary colic or gall?stone$ or cholecystitis or cholecystolithiasis).tw.
28. ((pain or biliary symptom$) adj5 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
29. or/21-28
30. exp "Cholecystectomy/"
31. cholecystectomy$.ti.
32. ((excis$ or remov$) adj2 gall?bladder).tw.
33. ((surgery or surgical) adj3 (cholecystitis or cholecystolithiasis or gall?bladder)).tw.
34. or/30-33
35. exp "costs and cost analysis"/
36. economics/
37. exp economics,hospital/
38. exp economics,medical/
39. economics,pharmaceutical/
40. exp budgets/
41. exp models, economic/
42. exp decision theory/
43. ec.fs.
44. monte carlo method/
45. markov chains/
46. exp health status indicators/
47. cost$.ti.
48. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab.
49. economic$ model$.tw.
50. (economic$ or pharmacoeconomic$ or pharmaco-economic$).tw.
51. (price$ or pricing).tw.
52. (financial or finance or finances or financed).tw.
53. ((value adj2 money) or monetary).tw.
54. markov$.tw.
55. monte carlo.tw.
56. (decision$ adj2 (tree? or analy$ or model$)).tw.
57. (standard adj1 gamble).tw.
58. trade off.tw.
59. or/35-56
60. 29 and 34 and 59
61. exp animals/ not humans/
62. 60 not 61
63. remove duplicates from 62
64. limit 63 to yr="1980 -Current"
65. 20 not 64
66. limit 65 to yr="1980 -Current"
# Appendix 2  Full-text screening form

## Cholecystectomy review: Full text screening form

<table>
<thead>
<tr>
<th>Study identifier</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Surname of first author + year of publication)</td>
<td></td>
</tr>
</tbody>
</table>

## Type of study

<table>
<thead>
<tr>
<th>Q1. Is the study either:</th>
<th>Yes</th>
<th>Unclear</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>An RCT in which people are randomized to receive either Cholecystectomy (open or laparoscopic) or observation/conservative treatment?</td>
<td>Go to next section</td>
<td>Exclude</td>
<td></td>
</tr>
<tr>
<td>A non-randomised comparative study in which people receive either cholecystectomy (open or laparoscopic) or observation/conservative treatment?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Participants in the study

<table>
<thead>
<tr>
<th>Q2. Are the participants all of the following:</th>
<th>Yes</th>
<th>Unclear</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults (18 years &amp; older or as defined by the trialists)?</td>
<td>Go to next section</td>
<td>Exclude</td>
<td></td>
</tr>
<tr>
<td>With first episode of symptomatic gallstones (biliary colic or cholecystitis)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligible for Cholecystectomy?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If diagnosed with cholecystitis, was it acute, mild, uncomplicated cholecystitis</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Outcomes reported

<table>
<thead>
<tr>
<th>Q3. Does the study report any of the following:</th>
<th>Yes</th>
<th>Unclear</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrence of symptoms?</td>
<td>Go to next section</td>
<td>Exclude</td>
<td></td>
</tr>
<tr>
<td>Complications (e.g. pancreatitis)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No of visits to primary care settings or hospital emergency dept?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analgesic requirements?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Need for surgical, endoscopic or radiological intervention?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Need for further medical intervention?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery-related morbidity (e.g. bile duct injury, infection, bleeding, reoperation rate, recurrent pain, diarrhoea)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality of life?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost of initial and any subsequent treatments?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Decision

<table>
<thead>
<tr>
<th>Include</th>
<th>Unclear</th>
<th>Exclude</th>
</tr>
</thead>
</table>

## Appendix 3  Data extraction form

<table>
<thead>
<tr>
<th>First author &amp; year:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Journal:</td>
<td>Extractor initials: Date:</td>
</tr>
<tr>
<td>Study aim:</td>
<td></td>
</tr>
<tr>
<td>Participants (i.e. Adults with first episode of symptomatic gallstones and being considered for Cholecystectomy in a secondary care setting):</td>
<td></td>
</tr>
<tr>
<td>Intervention:</td>
<td></td>
</tr>
<tr>
<td>Surgical removal of gallbladder:</td>
<td></td>
</tr>
<tr>
<td>- Open</td>
<td></td>
</tr>
<tr>
<td>- Laparoscopic</td>
<td></td>
</tr>
<tr>
<td>Comparator:</td>
<td></td>
</tr>
<tr>
<td>- Observation and/or</td>
<td></td>
</tr>
<tr>
<td>- Conservative treatment (give details below)</td>
<td></td>
</tr>
<tr>
<td>Study design:</td>
<td></td>
</tr>
<tr>
<td>- RCT</td>
<td></td>
</tr>
<tr>
<td>- Non-randomised comparative study</td>
<td></td>
</tr>
<tr>
<td>Setting:</td>
<td></td>
</tr>
<tr>
<td>Multicentre study?</td>
<td></td>
</tr>
<tr>
<td>- Yes (give number of centres __________ )</td>
<td></td>
</tr>
<tr>
<td>- No</td>
<td></td>
</tr>
<tr>
<td>Study start/end dates:</td>
<td></td>
</tr>
<tr>
<td>Duration of study:</td>
<td></td>
</tr>
</tbody>
</table>
Country: 

Source of funding: 

Additional information on study design: 

Method of patient recruitment: 

Inclusion criteria: 

Exclusion criteria: 

<table>
<thead>
<tr>
<th>Characteristics of participants</th>
<th>Group 1</th>
<th>Group 2</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enrolled, n</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomised, n</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Received treatment, n</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Post-randomisation exclusions, n

### Analysed, n

### Lost to follow-up, n

### Sex:
- **Male (n, %)**
- **Female (n, %)**

### Age:
- **Mean (SD)**
- **Median (range)**

### Ethnicity:
- **Caucasian**
- **Black**
- **South Asian**
- **Far East Asian**
- **Chinese**

### Diagnosis:
- **Biliary colic, n**
- **Cholecystitis, n**

### Previous ‘gallstones attacks’

### Concomitant disease
<table>
<thead>
<tr>
<th>Type of gallstones</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline QoL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASA score</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional patient information:

**Characteristics of interventions**

**Intervention: Surgical removal of gallbladder**

Type of surgery:

Type of incision:

Delay between presenting to secondary care & surgery:

Cost of operation:

Any other information:

**Comparator: Observation (watchful waiting) and/or conservative treatment**

Type:

Duration:

Cost:
No of patients requiring surgery:

Any other information:

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Group 1</th>
<th>Group 2</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrence of symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of visits to primary care or hospital ED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analgesic requirements</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervention needed?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endoscopic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiological</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Further medical intervention needed? E.g. incidental cancer diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery-related morbidity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality of life</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost of initial and any subsequent treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other important outcomes reported</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Appendix 4  Risk of bias form

<table>
<thead>
<tr>
<th>Risk of bias items (All studies)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Random sequence generation:</strong> Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</td>
</tr>
<tr>
<td><strong>Allocation concealment:</strong> Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment.</td>
</tr>
<tr>
<td><strong>Blinding of participants &amp; personnel:</strong> For each main outcome, describe all measures used, if any, to blind study participants &amp; personnel from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.</td>
</tr>
<tr>
<td><strong>Blinding of outcome assessment:</strong> For each main outcome, describe all measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.</td>
</tr>
<tr>
<td><strong>Incomplete outcome data:</strong> Describe the completeness of outcome data for each main outcome, including attrition &amp; exclusions from analysis. State whether attrition &amp; exclusions were reported, the numbers in each intervention group (compared with total randomised participants), reasons for attrition/exclusions where reported &amp; any re-inclusions in analyses performed by the review authors.</td>
</tr>
<tr>
<td><strong>Selective reporting:</strong> State how the possibility of selective outcome reporting was examined by the review authors &amp; what was found.</td>
</tr>
<tr>
<td><strong>Other sources of bias:</strong> State any important concerns about bias not addressed in the other domains in the tool. If particular questions/entries were pre-specified in the review’s protocol, responses should be provided for each question/entry</td>
</tr>
</tbody>
</table>
## Risk of bias items (Non-randomised studies only)

<table>
<thead>
<tr>
<th>Question</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Was clear information provided on the way in which groups/cohorts were recruited? (Yes/No/Unclear)</td>
<td>Identification of participants?</td>
</tr>
<tr>
<td></td>
<td>Assessment of baseline &amp; allocation to intervention?</td>
</tr>
<tr>
<td></td>
<td>Assessment of outcomes?</td>
</tr>
<tr>
<td></td>
<td>Generation of hypotheses?</td>
</tr>
<tr>
<td>Which parts of the study were prospective? (Yes/No/Unclear)</td>
<td>Baseline assessment of outcome variables?</td>
</tr>
<tr>
<td></td>
<td>Potential confounders?</td>
</tr>
</tbody>
</table>

## Confounders (Non-randomised studies only)

<table>
<thead>
<tr>
<th>Did the study...</th>
<th>Age</th>
<th>Sex</th>
<th>BMI</th>
<th>Smoking</th>
<th>Other medical problems</th>
<th>Other conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>... restrict participant selection so that all groups had the same value for the named confounder?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>... demonstrate balance between groups for the confounder?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>... match on the confounder?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>... adjust for the confounder in statistical analyses to quantify the effect size?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix 5  List of included and excluded studies

Included studies

Schmidt et al. 2011
Schmidt M, Søndenaa K, Vetrhus M, Berhane T, Eide GE. A randomized controlled study of uncomplicated gallstone disease with a 14-year follow up showed that operation was the preferred treatment. Dig Surg 2011;28:270–6.

Secondary publications:

Schmidt et al. 2011

Secondary publications

Excluded studies

Ineligible comparator


**Ineligible study design**


Goldfinger SE. By the way, doctor... Last month I had a night of severe abdominal pain. My doctor ordered an ultrasound test, and it showed gallstones. She is recommending surgery to remove my gallbladder, but I’d rather not have an operation because of this one episode. Is it dangerous to hold off on surgery? Is there any diet to follow or medicine I can take to prevent another attack? I am 53 years old and healthy. *Harv Health Lett* 1999;24:3.


**Ineligible population**


**No relevant outcomes**


**Unavailable**


This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.